Ancestry,DevStatus,DevStatusId,Drug,DrugId,Endpoint,Indication,IndicationId,OriginatorSponsored,Patients,ProtocolTitle,TrialEndDateActual,TrialEndDateCalc,TrialEndDateEstimate,TrialEndDateGiven,TrialId,TrialStartDate,TrialStatus
null,Phase 2a Clinical,C2A,SQ-109,31010,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,90,EBA of SQ-109 in Adult Subjects with Pulmonary TB,2012-05-31 00:00:00,2013-03-21 12:00:00,null,2012-05-31 00:00:00,71188,2010-11-30 00:00:00,Completed
Japanese Ancestry,Phase Not Applicable,PNA,moxifloxacin,12978,"Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,39,The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects,2013-01-31 00:00:00,2013-06-02 00:00:00,null,2013-01-31 00:00:00,139433,2011-11-30 00:00:00,Completed
null,Phase 3 Clinical,C3,ofloxacin,52139,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,420,Randomized Clinical Trial to Study the Efficacy and Tolerability of a 4-Month Regimen Containing Ofloxacin Compared to the Standard 6-Month Regimen in the Treatment of Patients with Superficial Lymphnode Tuberculosis,null,2015-02-09 12:00:00,null,null,142516,2012-10-20 00:00:00,Recruiting
null,Phase 2b Clinical,C2B,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,240,"A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis",2018-02-07 00:00:00,2017-02-11 12:00:00,null,2018-02-07 00:00:00,210646,2014-10-23 00:00:00,Completed
null,Phase 2 Clinical,C2,HE-2000,19980,Efficacy,Mycobacterium tuberculosis infection,221,N,25,"A phase II pilot, placebo-controlled study to evaluate the efficacy of HE-2000 on opportunistic infections such as tuberculosis (TB) in late-stage AIDS patients",null,2004-03-06 12:00:00,null,null,9820,2002-02-04 00:00:00,Status not specified
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,214,"Safety, Immunogenicity and Impact of MVA-85A, on the Immunogenicity of the EPI Vaccines",2009-12-31 00:00:00,2009-02-19 12:00:00,null,2009-12-31 00:00:00,52375,2006-10-31 00:00:00,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,12,"A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously",2005-03-31 00:00:00,2005-10-19 12:00:00,null,2005-03-31 00:00:00,10873,2003-06-30 00:00:00,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,24,"A Study of two Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG",2007-09-30 00:00:00,2008-02-20 12:00:00,null,2007-09-30 00:00:00,10944,2005-10-31 00:00:00,Completed
null,Phase not specified,NS,stavudine,4481,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,18,"A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment",null,2014-03-24 12:00:00,null,null,100728,2012-01-17 00:00:00,Status not specified
null,Phase not specified,NS,lamivudine,3474,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,18,"A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment",null,2014-03-24 12:00:00,null,null,100728,2012-01-17 00:00:00,Status not specified
null,Phase 1 Clinical,C1,"Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva",53784,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,20,A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers,2009-06-30 00:00:00,2010-01-19 12:00:00,null,2009-06-30 00:00:00,58503,2007-09-30 00:00:00,Completed
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,47,"A phase II, randomized, placebo-controlled study assessing the safety and efficacy of TMC-207 in patients with multidrug-resistant tuberculosis",null,2011-09-23 12:00:00,null,null,57685,2009-06-03 00:00:00,Recruiting
null,Phase 2b Clinical,C2B,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,240,"A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis",2018-02-07 00:00:00,2017-02-11 12:00:00,null,2018-02-07 00:00:00,210646,2014-10-23 00:00:00,Completed
null,Phase 1 Clinical,C1,moxifloxacin,12978,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,24,"Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults",2011-01-31 00:00:00,2011-12-02 00:00:00,null,2011-01-31 00:00:00,198748,2010-05-31 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,3573,Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Healthy Adults,2018-11-16 00:00:00,2016-12-08 12:00:00,null,2018-11-16 00:00:00,102580,2014-08-19 00:00:00,Completed
null,Phase 2 Clinical,C2,RUTI,57308,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,90,"Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI Following 1 Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection",2011-05-31 00:00:00,2012-10-19 12:00:00,null,2011-05-31 00:00:00,67014,2010-06-30 00:00:00,Completed
null,Phase 4 Clinical,C4,tenofovir disoproxil fumarate,14493,Safety,Mycobacterium tuberculosis infection,221,N,156,Appropriate Timing of HAART in Co-infected HIV/TB Patients,2011-05-31 00:00:00,2012-03-31 00:00:00,2013-10-31 00:00:00,2011-05-31 00:00:00,61991,2009-10-31 00:00:00,Terminated
null,Phase 2b Clinical,C2B,lopinavir + ritonavir,14681,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,71,Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV,2017-06-28 00:00:00,2015-12-12 00:00:00,null,2017-06-28 00:00:00,87585,2013-07-13 00:00:00,Terminated
null,Phase 1 Clinical,C1,pretomanid,13323,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,23,"A phase I, controlled study to evaluate the pharmacokinetics and efficacy of PA-824 in patients with tuberculosis",null,2013-01-02 12:00:00,null,null,70963,2010-09-13 00:00:00,Status not specified
null,Phase 2b Clinical,C2B,raltegravir,54488,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,71,Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV,2017-06-28 00:00:00,2015-12-12 00:00:00,null,2017-06-28 00:00:00,87585,2013-07-13 00:00:00,Terminated
null,Phase 2 Clinical,C2,moxifloxacin,12978,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,72,TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment,2007-08-31 00:00:00,2006-11-20 12:00:00,null,2007-08-31 00:00:00,10847,2004-07-31 00:00:00,Completed
null,Phase 2 Clinical,C2,moxifloxacin,12978,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,23,Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia,2006-05-31 00:00:00,2008-05-22 12:00:00,2006-12-31 00:00:00,2006-05-31 00:00:00,10860,2006-01-31 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,levofloxacin,3492,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,70,"Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis",2007-12-31 00:00:00,2006-06-20 12:00:00,null,2007-12-31 00:00:00,10869,2004-02-29 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,SSI H56-IC31,74849,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,98,A Phase I/IIa Safety And Immunogenicity of AERAS-456 in HIV-Negative Adults With And Without Latent Tuberculosis Infection,2015-11-30 00:00:00,2015-12-21 12:00:00,null,2015-11-30 00:00:00,136263,2013-08-31 00:00:00,Completed
null,Phase 1 Clinical,C1,AERAS-402,53975,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,12,A Study to Evaluate Safety and Immunogenicity of AERAS-402,2012-03-31 00:00:00,2013-06-19 12:00:00,null,2012-03-31 00:00:00,78482,2011-02-28 00:00:00,Completed
African Ancestry,Phase not specified,NS,"artenimol + piperaquine (malaria), Sigma-Tau",53724,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,36,Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients,null,2015-01-31 00:00:00,2014-01-31 00:00:00,2014-01-31 00:00:00,142485,2013-01-31 00:00:00,Not yet recruiting
null,Phase 4 Clinical,C4,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,9,Pharmacokinetics and Safety of Moxifloxacin,2016-08-31 00:00:00,2013-09-19 12:00:00,null,2016-08-31 00:00:00,76086,2011-05-31 00:00:00,Terminated
null,Phase 2 Clinical,C2,pretomanid,13323,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,105,Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z),2013-05-31 00:00:00,2015-02-20 12:00:00,null,2013-05-31 00:00:00,92275,2012-10-31 00:00:00,Completed
null,Phase 4 Clinical,C4,NeisVac-C,10774,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,28,A Study of the Interaction Between BCG And MenC Immunization,2018-06-27 00:00:00,2016-08-01 00:00:00,null,2018-06-27 00:00:00,162886,2014-06-20 00:00:00,Completed
null,Phase not specified,NS,efavirenz,10172,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,312,Pharmacokinetics of efavirenz in combination of rimfampin in HIV-infected adults,null,null,null,null,145595,null,Completed
null,Phase 3 Clinical,C3,lamivudine,3474,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,642,A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients,2010-07-31 00:00:00,2007-09-05 12:00:00,null,2010-07-31 00:00:00,201474,2005-06-30 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,H4:IC31,48499,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,243,"Phase I/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants",2017-12-22 00:00:00,2015-10-21 12:00:00,null,2017-12-22 00:00:00,134374,2013-07-01 00:00:00,Completed
null,Phase 3 Clinical,C3,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1004,TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis,2001-03-31 00:00:00,1997-08-19 12:00:00,null,2001-03-31 00:00:00,10650,1995-04-30 00:00:00,Completed
null,Phase 4 Clinical,C4,lamivudine,3474,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,130,Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg,2012-10-31 00:00:00,2009-04-07 12:00:00,null,2012-10-31 00:00:00,11181,2007-01-31 00:00:00,Terminated
null,Phase 4 Clinical,C4,Menitorix,11458,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,28,A Study of the Interaction Between BCG And MenC Immunization,2018-06-27 00:00:00,2016-08-01 00:00:00,null,2018-06-27 00:00:00,162886,2014-06-20 00:00:00,Completed
null,Phase 3 Clinical,C3,lopinavir + ritonavir,14681,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1107,Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults,2015-01-31 00:00:00,2010-06-06 12:00:00,null,2015-01-31 00:00:00,195741,2008-03-31 00:00:00,Completed
null,Phase 2 Clinical,C2,rifalazil,8658,Efficacy,Mycobacterium tuberculosis infection,221,N,60,"A randomized, multiple-dose, open-label, phase II clinical study to evaluate the early bactericidal activity of rifalazil (PA-1648) and isoniazid (INH), as compared with INH alone or INH plus rifampin in patients with tuberculosis",null,2000-02-09 12:00:00,null,null,20175,1997-10-20 00:00:00,Completed
null,Phase 1 Clinical,C1,MTBVAC,89744,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,36,Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine,2014-11-30 00:00:00,2015-05-23 12:00:00,null,2014-11-30 00:00:00,164024,2013-01-31 00:00:00,Completed
null,Phase 4 Clinical,C4,zidovudine,44316,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,130,Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg,2012-10-31 00:00:00,2009-04-07 12:00:00,null,2012-10-31 00:00:00,11181,2007-01-31 00:00:00,Terminated
null,Phase 3b Clinical,C3B,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,113,Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection,null,2017-06-23 00:00:00,2019-12-31 00:00:00,2019-12-31 00:00:00,201302,2015-01-23 00:00:00,No longer recruiting
null,Phase 3 Clinical,C3,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,642,A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients,2010-07-31 00:00:00,2007-09-05 12:00:00,null,2010-07-31 00:00:00,201474,2005-06-30 00:00:00,Completed
null,Phase 4 Clinical,C4,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,827,"An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis",2012-11-30 00:00:00,2010-12-05 12:00:00,null,2012-11-30 00:00:00,153990,2008-08-15 00:00:00,Completed
null,Phase 1 Clinical,C1,AEC/BC02,81363,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,135,Freeze-dried recombinant tuberculosis vaccine (AEC/BC02) phase I clinical human tolerance test,null,null,null,null,329497,null,Not yet recruiting
null,Phase 2 Clinical,C2,rifapentine,15102,Safety,Mycobacterium tuberculosis infection,221,N,150,TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis,2003-06-30 00:00:00,2001-11-19 12:00:00,2003-02-28 00:00:00,2003-06-30 00:00:00,8751,1999-07-31 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,rifapentine,15102,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,50,"Evaluating the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection",2019-04-10 00:00:00,2019-06-07 12:00:00,null,2019-04-10 00:00:00,250483,2017-02-15 00:00:00,Completed
null,Phase 3 Clinical,C3,rifapentine,15102,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,2516,Rifapentine-containing Tuberculosis Treatment Shortening Regimens,null,2018-05-16 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,226815,2016-01-25 00:00:00,No longer recruiting
null,Phase not specified,NS,"ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82062,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,30,The Efficacy and Safety of Early Double J Stent Placement in Treatment of Renal Tuberculosis: A Novel Renal Function Protective Strategy,null,2014-09-26 12:00:00,null,null,132105,2012-06-06 00:00:00,Recruiting
null,Phase 3 Clinical,C3,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,2516,Rifapentine-containing Tuberculosis Treatment Shortening Regimens,null,2018-05-16 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,226815,2016-01-25 00:00:00,No longer recruiting
null,Phase 3 Clinical,C3,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,284,Shortening Treatment by Advancing Novel Drugs,2018-05-31 00:00:00,2017-06-19 12:00:00,null,2018-05-31 00:00:00,221844,2015-02-28 00:00:00,Completed
null,Phase 1b Clinical,C1B,macozinone,90085,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,32,"Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ-169 in Multiple Dosing",null,2021-06-12 12:00:00,2019-10-31 00:00:00,2019-10-31 00:00:00,363587,2019-02-21 00:00:00,Recruiting
null,Phase 2 Clinical,C2,"amoxicillin + clavulanate potassium, GSK",44284,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,30,"Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis",2014-12-31 00:00:00,2017-01-19 12:00:00,null,2014-12-31 00:00:00,220739,2014-09-30 00:00:00,Completed
null,Phase 2 Clinical,C2,"amoxicillin + clavulanate potassium, GSK",44284,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,45,Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers,null,2021-04-21 12:00:00,2019-04-30 00:00:00,2019-04-30 00:00:00,224111,2018-12-31 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,"amoxicillin + clavulanate potassium, GSK",44284,"Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,36,Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers,2015-10-31 00:00:00,2017-01-28 00:00:00,null,2015-10-31 00:00:00,224811,2015-02-28 00:00:00,Completed
null,Phase 1 Clinical,C1,macozinone,90085,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,35,Phase I Study of PBTZ-169,2016-11-30 00:00:00,2018-05-22 12:00:00,null,2016-11-30 00:00:00,286724,2016-01-31 00:00:00,Completed
null,Phase 2 Clinical,C2,nitazoxanide,11089,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,30,A 14-Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis,2018-04-11 00:00:00,2018-06-20 12:00:00,null,2018-04-11 00:00:00,253491,2016-02-29 00:00:00,Completed
null,Phase not specified,NS,moxifloxacin,12978,"Bioequivalence,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,42,"Open, randomized, crossover study of comparative pharmacokinetics and bioequivalence of drugs Moxifloxacin tablets, film-coated, 400 mg (JSC ""Pharmasyntez"", Russia) and Avelox tablets, film-coated, 400 mg (""Bayer Pharma AG"", Germany)",null,2017-05-26 00:00:00,2016-10-01 00:00:00,2016-10-01 00:00:00,247038,2015-11-23 00:00:00,Status not specified
null,Phase not specified,NS,lamivudine,3474,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,592,Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings,null,2011-11-06 12:00:00,null,null,8820,2009-08-31 00:00:00,Completed
null,Phase not specified,NS,Perchlozone,87251,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,120,"An Open, Prospective, Comparative, Randomized, Controlled Clinical Trial Of Efficacy And Safety Perhlozone Capsules (JSC 'Pharmasyntez', Russia), Used In Doses Of 9.5 And 12.5 mg/kg Night In The Complex Treatment Of Pulmonary Tuberculosis",null,2015-05-20 12:00:00,2014-10-09 00:00:00,2014-10-09 00:00:00,169098,2013-01-28 00:00:00,Status not specified
null,Phase 0 Clinical,C0,efavirenz,10172,Efficacy,Mycobacterium tuberculosis infection,221,N,419,TasP in Correctional Facilities,2018-03-31 00:00:00,2018-04-08 12:00:00,null,2018-03-31 00:00:00,280225,2016-02-01 00:00:00,Completed
null,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,640,Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis,null,2020-04-26 00:00:00,2022-10-01 00:00:00,2022-10-01 00:00:00,293087,2018-02-08 00:00:00,Recruiting
null,Phase 2 Clinical,C2,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,62,PK Study of Rifampicin Interactions With DMPA and Efaviranz in TB,2017-06-15 00:00:00,2018-04-03 00:00:00,null,2017-06-15 00:00:00,227340,2015-11-03 00:00:00,Completed
null,Phase 1 Clinical,C1,Ad5Ag85A,71323,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,28,Phase I Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol,null,2019-12-26 12:00:00,2021-04-30 00:00:00,2021-04-30 00:00:00,219950,2017-09-05 00:00:00,Recruiting
null,Phase 1 Clinical,C1,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,155,Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children,2016-03-31 00:00:00,2012-01-06 12:00:00,null,2016-03-31 00:00:00,37985,2009-10-31 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,500,Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB (rhIL-2),null,2011-09-21 12:00:00,2020-03-01 00:00:00,2020-03-01 00:00:00,289837,2009-06-01 00:00:00,Recruiting
null,Phase 2 Clinical,C2,delamanid,16545,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,213,"A Phase II, Multicenter, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683",2011-09-30 00:00:00,2011-07-21 12:00:00,null,2011-09-30 00:00:00,242789,2009-03-31 00:00:00,Completed
null,Phase 3 Clinical,C3,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,750,Evaluating Newly Approved Drugs for Multidrug-resistant TB,null,2019-04-02 00:00:00,2021-04-30 00:00:00,2021-04-30 00:00:00,259506,2016-12-31 00:00:00,Recruiting
null,Phase 2 Clinical,C2,verapamil,44437,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,69,Verapamil Dose-finding Study in Adult Patients with Tuberculosis,null,2018-10-05 12:00:00,null,null,261260,2016-06-15 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,tenofovir disoproxil fumarate,14493,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,460,Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis,null,2018-02-28 00:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,214156,2015-09-30 00:00:00,Recruiting
null,Phase 2a Clinical,C2A,pretomanid,13323,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,69,Phase IIa Evaluation of Early Bactericidal Activity of PA-824 in Pulmonary Tuberculosis,2007-12-31 00:00:00,2009-12-20 12:00:00,null,2007-12-31 00:00:00,9381,2007-08-31 00:00:00,Completed
null,Phase 3 Clinical,C3,metformin hydrochloride,6050,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,60,Effect of metformin on sputum smear conversion in pulmonary tuberculosis with type 2 diabetes mellitus,null,2021-06-20 12:00:00,null,null,370128,2019-03-01 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,pretomanid,13323,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,6,"A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects",2006-05-31 00:00:00,2008-07-20 12:00:00,null,2006-05-31 00:00:00,303299,2006-03-31 00:00:00,Completed
null,Phase 0 Clinical,C0,tenofovir disoproxil fumarate,14493,Efficacy,Mycobacterium tuberculosis infection,221,N,419,TasP in Correctional Facilities,2018-03-31 00:00:00,2018-04-08 12:00:00,null,2018-03-31 00:00:00,280225,2016-02-01 00:00:00,Completed
null,Phase 1a Clinical,C1A,SQ-109,31010,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,62,"A phase Ia, Placebo-controlled, Dose-Escalating study to test the Safety, Tolerability and Pharmacokinetics of Single dose of SQ-109 in 62 Healthy Subjects",2007-05-03 00:00:00,2009-01-19 16:46:54,null,2007-05-03 00:00:00,8945,2006-09-30 04:46:54,Completed
Asian Ancestry,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,400,Short Intensive Treatment For Children With Tuberculous Meningitis,null,2020-03-20 00:00:00,2022-08-01 00:00:00,2022-08-01 00:00:00,360104,2018-01-02 00:00:00,Not yet recruiting
Japanese Ancestry,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,400,Short Intensive Treatment For Children With Tuberculous Meningitis,null,2020-03-20 00:00:00,2022-08-01 00:00:00,2022-08-01 00:00:00,360104,2018-01-02 00:00:00,Not yet recruiting
null,Phase 2/Phase 3 Clinical,C23,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,630,Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s),null,2019-05-23 12:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,244304,2017-01-31 00:00:00,Recruiting
null,Phase 2 Clinical,C2,rosuvastatin,12420,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,50,Effect of rosuvastatin on HIV TB coinfection,null,2019-06-07 12:00:00,null,null,292154,2017-04-01 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,AERAS-402,53975,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,20,"A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB",2010-07-31 00:00:00,2011-01-20 12:00:00,null,2010-07-31 00:00:00,228651,2008-09-30 00:00:00,Completed
null,Phase not specified,NS,azithromycin,2587,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy,null,2002-01-02 00:00:00,null,null,8647,1999-11-02 00:00:00,Completed
null,Phase 3 Clinical,C3,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,500,The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB,null,2021-06-27 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,369109,2019-03-08 00:00:00,Recruiting
null,Phase 1 Clinical,C1,linezolid,11036,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,31,Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis,2018-12-31 00:00:00,2018-02-23 12:00:00,null,2018-12-31 00:00:00,261481,2015-11-04 00:00:00,Completed
null,Phase 2 Clinical,C2,faropenem,4492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,400,"Prospective, Randomized Control, Non-inferiority Study of the Use of Faropenem for Patients with etiology Positive Pulmonary Tuberculosis",null,2020-09-03 12:00:00,2020-05-01 00:00:00,2020-05-01 00:00:00,338648,2018-05-15 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,GSK-3036656,70581,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,30,First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK-3036656 in Healthy Subjects,2017-08-04 00:00:00,2019-07-23 12:00:00,null,2017-08-04 00:00:00,290705,2017-04-02 00:00:00,Completed
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,167,"A prospective, unblinded, non-randomized, single-center study to evaluate outcomes of bedaquiline-included regimens in multidrug-resistance/extensively drug-resistant (MDR/XDR) tuberculosis patients after 24 months and to identify factors predisposing the long-term treatment success",null,null,null,null,361163,null,Status not specified
null,Phase 2 Clinical,C2,azithromycin,2587,"Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,24,Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis,null,2020-05-23 12:00:00,2019-04-30 00:00:00,2019-04-30 00:00:00,298743,2018-02-01 00:00:00,Recruiting
null,Phase 2 Clinical,C2,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,38,Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-Positive Adults,2006-05-31 00:00:00,2007-11-20 12:00:00,null,2006-05-31 00:00:00,9528,2005-07-31 00:00:00,Completed
null,Phase 2 Clinical,C2,delamanid,16545,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,A phase II trial to evaluate delamanid in pediatric patients with multi-drug resistance tuberculosis,null,null,null,null,341287,null,Status not specified
null,Phase 4 Clinical,C4,azithromycin,2587,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 2/Phase 3 Clinical,C23,bedaquiline,51310,Efficacy,Mycobacterium tuberculosis infection,221,N,54,Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial,null,2021-10-20 12:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,379769,2019-07-01 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,500,Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance,null,2021-09-29 00:00:00,2022-12-31 00:00:00,2022-12-31 00:00:00,375499,2019-06-30 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,ESAT-6CFP10,95442,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,1802,Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65 years (III-healthy),2016-10-31 00:00:00,2018-09-20 12:00:00,null,2016-10-31 00:00:00,262931,2016-05-31 00:00:00,Completed
null,Phase 2 Clinical,C2,"Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva",53784,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,240,THYB-04,null,2014-12-17 12:00:00,null,null,285704,2012-08-27 00:00:00,No longer recruiting
null,Phase 1 Clinical,C1,etoricoxib,22216,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,39,Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic,null,2018-03-21 12:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,235355,2015-11-30 00:00:00,No longer recruiting
null,Phase 3 Clinical,C3,"lamivudine + abacavir + zidovudine, GSK",26574,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,350,Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis,null,2007-01-06 12:00:00,null,null,8801,2004-10-31 00:00:00,Completed
null,Phase 3b Clinical,C3B,dolutegravir,59062,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,113,Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection,null,2017-06-23 00:00:00,2019-12-31 00:00:00,2019-12-31 00:00:00,201302,2015-01-23 00:00:00,No longer recruiting
null,Phase 1 Clinical,C1,OPC-167832,104447,Safety,Mycobacterium tuberculosis infection,221,Y,null,"A phase I, single-ascending-dose study of OPC-167832 for the treatment of Mycobacterium tuberculosis infection",2017-12-31 00:00:00,null,null,2017-12-31 00:00:00,327014,null,Completed
null,Phase 2 Clinical,C2,SSI H56-IC31,74849,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,900,Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence,null,2021-05-22 12:00:00,2022-12-31 00:00:00,2022-12-31 00:00:00,337957,2019-01-31 00:00:00,Recruiting
null,Phase 1 Clinical,C1,midazolam hydrochloride,44303,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,74,"A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371",2018-07-08 00:00:00,2019-12-19 12:00:00,null,2018-07-08 00:00:00,303756,2017-08-29 00:00:00,Completed
null,Phase 3 Clinical,C3,clarithromycin,2829,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,152,Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide,null,2016-08-19 12:00:00,2016-04-30 00:00:00,2016-04-30 00:00:00,183613,2014-04-30 00:00:00,Recruiting
null,Phase 4 Clinical,C4,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,160,"Is Levofloxacin Better Than Rifampicin in the Treatment of Tuberculous Meningitis- a Randomized, Control Study",null,2012-01-01 00:00:00,null,null,129005,2009-10-01 00:00:00,Recruiting
Asian Ancestry,Phase not specified,NS,stavudine,4481,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,400,Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China,null,2011-05-06 12:00:00,2013-06-30 00:00:00,2013-06-30 00:00:00,76946,2009-02-28 00:00:00,Recruiting
null,Phase 1 Clinical,C1,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,26,Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid,null,2019-03-22 00:00:00,2018-02-28 00:00:00,2018-02-28 00:00:00,265766,2016-10-21 00:00:00,Recruiting
Asian Ancestry,Phase not specified,NS,rifabutin,4229,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,400,Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China,null,2011-05-06 12:00:00,2013-06-30 00:00:00,2013-06-30 00:00:00,76946,2009-02-28 00:00:00,Recruiting
null,Phase 2 Clinical,C2,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,36,Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA-85A in BCG-vaccinated African Adolescents,2015-01-31 00:00:00,2016-10-19 12:00:00,null,2015-01-31 00:00:00,201409,2014-06-30 00:00:00,Completed
null,Phase 3 Clinical,C3,trimethoprim + sulphamethoxazole,44363,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,642,A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients,2010-07-31 00:00:00,2007-09-05 12:00:00,null,2010-07-31 00:00:00,201474,2005-06-30 00:00:00,Completed
null,Phase 2b Clinical,C2B,rifabutin,4229,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,71,Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV,2017-06-28 00:00:00,2015-12-12 00:00:00,null,2017-06-28 00:00:00,87585,2013-07-13 00:00:00,Terminated
null,Phase 2 Clinical,C2,efavirenz,10172,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,15,Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz,2004-02-01 00:00:00,2002-02-04 12:00:00,2004-02-29 00:00:00,2004-02-01 00:00:00,10657,1999-11-30 00:00:00,Completed
null,Phase not specified,NS,moxifloxacin,12978,"Bioequivalence,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,24,"A randomized, open, balanced, two-component, two-period, crossover, with a single-dose study of comparative pharmacokinetics and bioequivalence of Primflo (moxifloxacin) 400 mg (Dr Reddy's Laboratories Ltd, India) and Avilox  (moxifloxacin) 400 mg (Bayer Healthcare AG, Germany), when taken orally on an empty stomach in healthy adult volunteers",null,2014-04-13 00:00:00,2014-09-01 00:00:00,2014-09-01 00:00:00,167750,2012-10-10 00:00:00,Status not specified
Asian Ancestry,Phase not specified,NS,zidovudine,44316,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,400,Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China,null,2011-05-06 12:00:00,2013-06-30 00:00:00,2013-06-30 00:00:00,76946,2009-02-28 00:00:00,Recruiting
null,Phase 2 Clinical,C2,VPM-1002,55569,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,48,Study to Evaluate Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Newborn Infants in South Africa,2012-11-30 00:00:00,2014-03-21 12:00:00,null,2012-11-30 00:00:00,82764,2011-11-30 00:00:00,Completed
null,Phase not specified,NS,rifabutin,4229,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,520,"A multicenter, randomized, 6-month study to compare the efficacy, tolerability and toxicity of two different regimens of rifabutin with that of rifampicin",null,1997-04-21 12:00:00,null,null,15869,1994-12-31 00:00:00,Status not specified
null,Phase 1 Clinical,C1,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,16,TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP),2010-06-30 00:00:00,2011-11-29 00:00:00,null,2010-06-30 00:00:00,56959,2009-06-30 00:00:00,Completed
null,Phase 2a Clinical,C2A,sutezolid,11088,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,59,"PNU-100480 In Newly Diagnosed, Treatment Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay",2011-12-31 00:00:00,2013-12-20 12:00:00,null,2011-12-31 00:00:00,71511,2011-08-31 00:00:00,Completed
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,68,Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis,2010-09-30 00:00:00,2012-08-19 12:00:00,null,2010-09-30 00:00:00,71046,2010-04-30 00:00:00,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,Efficacy,Mycobacterium tuberculosis infection,221,Y,48,"A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA-85A",2012-01-31 00:00:00,2012-09-19 12:00:00,null,2012-01-31 00:00:00,69926,2010-05-31 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,indinavir,5321,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,20,The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin,2009-12-31 00:00:00,2009-03-07 12:00:00,2009-06-30 00:00:00,2009-12-31 00:00:00,10871,2006-12-31 00:00:00,Completed
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,433,TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment,2007-12-31 00:00:00,2008-06-19 12:00:00,null,2007-12-31 00:00:00,10685,2006-02-28 00:00:00,Completed
null,Phase 1 Clinical,C1,Ad5Ag85A,71323,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,24,Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine,2013-07-31 00:00:00,2011-10-20 12:00:00,null,2013-07-31 00:00:00,77668,2009-06-30 00:00:00,Terminated
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,48,"A Study of MVA-85A, in Asymptomatic Volunteers Infected With TB, HIV or Both",2011-01-31 00:00:00,2009-10-05 12:00:00,null,2011-01-31 00:00:00,14589,2007-07-31 00:00:00,Completed
null,Phase 4 Clinical,C4,abacavir,6242,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,10,Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients,null,2013-01-05 12:00:00,null,null,63729,2010-10-31 00:00:00,Recruiting
null,Phase 2 Clinical,C2,rifapentine,15102,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,529,Rifapentine During Intensive Phase Tuberculosis (TB) Treatment,2013-12-31 00:00:00,2011-04-22 12:00:00,null,2013-12-31 00:00:00,17237,2008-12-31 00:00:00,Completed
null,Phase 4 Clinical,C4,linezolid,11036,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,7,Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients,2012-11-30 00:00:00,2014-04-01 00:00:00,null,2012-11-30 00:00:00,182646,2011-12-31 00:00:00,Completed
null,Phase 2b Clinical,C2B,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,Phase IIb Clinical Study of new GSK Vaccine Candidate,null,2015-04-23 12:00:00,null,null,137219,2013-01-01 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,88,TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions,2011-04-30 00:00:00,2013-06-19 12:00:00,null,2011-04-30 00:00:00,74529,2011-02-28 00:00:00,Completed
null,Phase 3 Clinical,C3,lamivudine,3474,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,240,"Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone",2017-04-30 00:00:00,2015-12-20 12:00:00,null,2017-04-30 00:00:00,150793,2013-08-30 00:00:00,Completed
null,Phase 2 Clinical,C2,linezolid,11036,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,113,A Phase II Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients,2017-07-31 00:00:00,2017-03-21 12:00:00,null,2017-07-31 00:00:00,215072,2014-11-30 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,lamivudine,3474,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,570,Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients,2011-04-30 00:00:00,2010-03-07 12:00:00,2011-03-31 00:00:00,2011-04-30 00:00:00,10948,2007-12-31 00:00:00,Completed
null,Phase 2a Clinical,C2A,moxifloxacin,12978,"Safety,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,60,"Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study",2012-06-30 00:00:00,2013-02-19 12:00:00,null,2012-06-30 00:00:00,67996,2010-10-31 00:00:00,Completed
null,Phase 3 Clinical,C3,levofloxacin,3492,Efficacy,Mycobacterium tuberculosis infection,221,N,182,Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients,2012-10-31 00:00:00,2012-07-20 12:00:00,2012-02-29 00:00:00,2012-10-31 00:00:00,63801,2010-03-31 00:00:00,Terminated
null,Phase 3 Clinical,C3,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,295,Early Access of TMC-207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis,null,2014-01-05 12:00:00,null,null,82132,2011-09-16 00:00:00,Completed
null,Phase 1 Clinical,C1,IMM-201,11115,Efficacy,Mycobacterium tuberculosis infection,221,Y,101,"A phase I, randomized, study to evaluate the efficacy of SRL-172 on cell-mediated immunity of patients with pulmonary tuberculosis",null,2002-04-21 12:00:00,null,null,17288,1999-12-31 00:00:00,Status not specified
Japanese Ancestry,Phase 2 Clinical,C2,linezolid,11036,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,6,An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB),2018-11-08 00:00:00,2017-05-20 00:00:00,null,2018-11-08 00:00:00,222400,2015-02-18 00:00:00,Completed
null,Phase 3 Clinical,C3,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,540,Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis,2010-05-31 00:00:00,2008-04-07 12:00:00,null,2010-05-31 00:00:00,145651,2006-01-31 00:00:00,Completed
null,Phase 4 Clinical,C4,nevirapine,3700,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,5,A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV,2008-03-01 00:00:00,2009-10-05 12:00:00,2008-03-31 00:00:00,2008-03-01 00:00:00,11177,2007-07-31 00:00:00,Terminated
null,Phase 2/Phase 3 Clinical,C23,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,570,Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients,2011-04-30 00:00:00,2010-03-07 12:00:00,2011-03-31 00:00:00,2011-04-30 00:00:00,10948,2007-12-31 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,"BCG vaccine, Organon",13624,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,52,A Clinical Challenge Study of BCG in Healthy Volunteers,2015-01-31 00:00:00,2016-07-20 12:00:00,null,2015-01-31 00:00:00,177982,2014-03-31 00:00:00,Completed
null,Phase 2a Clinical,C2A,LL-3858,49162,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,40,A phase IIa clinical trial for a novel molecule (LL-3858) developed by Lupin Limited which has the potential of treating the Pulmonary tuberculosis patients effectively,null,2012-03-23 12:00:00,null,null,103573,2009-12-02 00:00:00,No longer recruiting
null,Phase not specified,NS,IMM-201,11115,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,2000,A five year study to evaluate the safety and efficacy of SRL-172 in the prevention of tuberculosis in HIV-positive subjects,null,2003-12-06 12:00:00,null,null,19967,2001-09-30 00:00:00,Status not specified
null,Phase not specified,NS,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,63,Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment,2011-02-28 00:00:00,2010-06-30 00:00:00,2011-12-31 00:00:00,2011-02-28 00:00:00,169697,2008-03-31 00:00:00,Terminated
null,Phase 1 Clinical,C1,nevirapine,3700,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,16,TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP),2010-06-30 00:00:00,2011-11-29 00:00:00,null,2010-06-30 00:00:00,56959,2009-06-30 00:00:00,Completed
Asian Ancestry,Phase not specified,NS,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,36,Moxifloxacin_QT Study in Chinese Healthy Volunteer,null,2014-02-03 12:00:00,2012-10-31 00:00:00,2012-10-31 00:00:00,89715,2012-07-31 00:00:00,Recruiting
null,Phase 3 Clinical,C3,stavudine,4481,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,145,Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin,2010-12-31 00:00:00,2009-04-07 12:00:00,null,2010-12-31 00:00:00,10947,2007-01-31 00:00:00,Completed
null,Phase 1 Clinical,C1,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,74,Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers,2012-12-31 00:00:00,2015-01-20 12:00:00,null,2012-12-31 00:00:00,90512,2012-09-30 00:00:00,Completed
null,Phase 2 Clinical,C2,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,114,Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease,null,2015-01-20 12:00:00,2014-09-30 00:00:00,2014-09-30 00:00:00,90788,2012-09-30 00:00:00,Recruiting
null,Phase 2 Clinical,C2,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,105,Interaction Between High-Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection,null,2016-03-07 12:00:00,2017-12-31 00:00:00,2017-12-31 00:00:00,161096,2013-12-31 00:00:00,No longer recruiting
null,Phase 4 Clinical,C4,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,44,Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment,2013-06-30 00:00:00,2014-01-29 00:00:00,null,2013-06-30 00:00:00,182316,2011-08-31 00:00:00,Terminated
null,Phase 1 Clinical,C1,rifapentine,15102,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,15,Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine,2008-08-24 00:00:00,2009-10-19 12:00:00,null,2008-08-24 00:00:00,10943,2007-06-30 00:00:00,Terminated
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,365,"Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design",2015-03-31 00:00:00,2015-08-20 12:00:00,null,2015-03-31 00:00:00,109063,2013-04-30 00:00:00,Completed
null,Phase 1 Clinical,C1,DAR-901,90231,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,59,Phase I Trial of DAR-901,2016-06-30 00:00:00,2016-06-19 12:00:00,null,2016-06-30 00:00:00,173446,2014-02-28 00:00:00,Completed
null,Phase 1 Clinical,C1,rifapentine,15102,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,37,"Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers",2011-03-31 00:00:00,2012-08-19 12:00:00,null,2011-03-31 00:00:00,68204,2010-04-30 00:00:00,Completed
null,Phase 3 Clinical,C3,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,283,"Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter, Randomized, Controlled Study in Taiwan",null,2016-12-20 12:00:00,2016-12-31 00:00:00,2016-12-31 00:00:00,207608,2014-08-31 00:00:00,No longer recruiting
null,Phase 2 Clinical,C2,albendazole,12132,Efficacy,Mycobacterium tuberculosis infection,221,N,120,Tuberculosis - Learning the Impact of Nutrition,null,2021-07-25 00:00:00,2023-12-31 00:00:00,2023-12-31 00:00:00,347635,2019-06-30 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1148,Tuberculosis Prevention for HIV Infected Adults,2009-06-30 00:00:00,2005-01-19 12:00:00,null,2009-06-30 00:00:00,8790,2002-09-30 00:00:00,Completed
null,Phase 1 Clinical,C1,sutezolid,11088,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,32,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid",2017-12-16 00:00:00,2020-01-16 12:00:00,null,2017-12-16 00:00:00,303595,2017-09-26 00:00:00,Completed
null,Phase 4 Clinical,C4,rifapentine,15102,Efficacy,Mycobacterium tuberculosis infection,221,N,450,Taima TB: 3-HP Study,null,2018-08-20 12:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,254050,2016-04-30 00:00:00,Recruiting
null,Phase 1 Clinical,C1,rifapentine,15102,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,75,Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers,null,2018-08-09 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,260814,2016-06-03 00:00:00,Recruiting
null,Phase Not Applicable,PNA,delpazolid,76307,Efficacy,Mycobacterium tuberculosis infection,221,Y,null,A clinical trial of RMX-2001 in multidrug-resistant tuberculosis (MDR-TB) in China,null,null,null,null,370697,null,Not yet recruiting
null,Phase 4 Clinical,C4,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,80,Research on New Regimens for Retreatment Pulmonary Tuberculosis,null,2015-10-20 12:00:00,2016-12-31 00:00:00,2016-12-31 00:00:00,220243,2013-06-30 00:00:00,Recruiting
null,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,530,The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB,null,2018-08-20 12:00:00,2022-06-30 00:00:00,2022-06-30 00:00:00,228190,2016-04-30 00:00:00,Recruiting
null,Phase 2/Phase 3 Clinical,C23,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,300,An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis,null,2018-02-19 12:00:00,2019-01-31 00:00:00,2019-01-31 00:00:00,230529,2015-10-31 00:00:00,Recruiting
null,Phase 3 Clinical,C3,lamivudine,3474,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,460,Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis,null,2018-02-28 00:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,214156,2015-09-30 00:00:00,Recruiting
null,Phase 0 Clinical,C0,lamivudine,3474,Efficacy,Mycobacterium tuberculosis infection,221,N,419,TasP in Correctional Facilities,2018-03-31 00:00:00,2018-04-08 12:00:00,null,2018-03-31 00:00:00,280225,2016-02-01 00:00:00,Completed
null,Phase 2 Clinical,C2,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,500,"A 9-Month Isoniazid versus 3-Month Isoniazid plus Rifapentine for Treatment of Tuberculosis Infection in Rheumatic Patients: a Randomized, Controlled Trial",null,2019-12-22 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,352748,2017-09-01 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,cefadroxil,46931,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,45,Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers,null,2021-04-21 12:00:00,2019-04-30 00:00:00,2019-04-30 00:00:00,224111,2018-12-31 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,750,Evaluating Newly Approved Drugs for Multidrug-resistant TB,null,2019-04-02 00:00:00,2021-04-30 00:00:00,2021-04-30 00:00:00,259506,2016-12-31 00:00:00,Recruiting
null,Phase not specified,NS,moxifloxacin,12978,Efficacy,Mycobacterium tuberculosis infection,221,N,null,The research of new regimen for multidrug-resistant tuberculosis treatment,null,2011-01-21 12:00:00,2010-12-31 00:00:00,2010-12-31 00:00:00,244777,2008-10-01 00:00:00,No longer recruiting
null,Phase 2 Clinical,C2,lamivudine,3474,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,230,Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis,null,2020-08-28 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,334027,2018-04-15 00:00:00,Recruiting
null,Phase 4 Clinical,C4,rifabutin,4229,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,200,RIFART,2011-04-19 00:00:00,2007-05-21 12:00:00,null,2011-04-19 00:00:00,131240,2005-03-15 00:00:00,Terminated
null,Phase 4 Clinical,C4,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,488,NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB,null,2020-11-24 12:00:00,2024-08-04 00:00:00,2024-08-04 00:00:00,348056,2018-08-05 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,GC-3107,108779,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,20,Study to Investigate the Safety and Efficacy of GC-3107 (BCG Vaccine) in Healthy Adults,null,2020-04-04 12:00:00,2018-03-31 00:00:00,2018-03-31 00:00:00,321760,2017-12-14 00:00:00,Recruiting
null,Phase 1 Clinical,C1,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,75,A Comparative study of different treatment regimes for brain tuberculosis,null,2021-09-15 12:00:00,null,null,382387,2019-05-27 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,rifabutin,4229,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,15,A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects,2008-10-01 00:00:00,2010-11-06 12:00:00,null,2008-10-01 00:00:00,25327,2008-08-31 00:00:00,Terminated
null,Phase 2b Clinical,C2B,rifabutin,4229,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,183,Assessing PA-824 for Tuberculosis,null,2017-08-18 12:00:00,2021-09-30 00:00:00,2021-09-30 00:00:00,213394,2015-04-29 00:00:00,Recruiting
null,Phase 2 Clinical,C2,faropenem,4492,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,30,"Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis",2014-12-31 00:00:00,2017-01-19 12:00:00,null,2014-12-31 00:00:00,220739,2014-09-30 00:00:00,Completed
null,Phase 3 Clinical,C3,delamanid,16545,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB",null,2022-05-22 12:00:00,null,null,368916,2020-01-31 00:00:00,Terminated
null,Phase 2 Clinical,C2,delamanid,16545,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,84,"Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis",null,2019-01-30 00:00:00,2021-01-15 00:00:00,2021-01-15 00:00:00,243619,2016-08-31 00:00:00,No longer recruiting
null,Phase 3 Clinical,C3,rifabutin,4229,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,30,Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso,null,2016-04-28 00:00:00,2014-11-27 00:00:00,2014-11-27 00:00:00,161441,2013-11-28 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,rifapentine,15102,Efficacy,Mycobacterium tuberculosis infection,221,N,2500,Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349),null,2020-11-08 12:00:00,null,null,347338,2018-07-20 00:00:00,Not yet recruiting
null,Phase 2/Phase 3 Clinical,C23,pretomanid,13323,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,630,Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s),null,2019-05-23 12:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,244304,2017-01-31 00:00:00,Recruiting
null,Phase 1 Clinical,C1,S-004992,61340,Safety,Mycobacterium tuberculosis infection,221,N,null,A phase I study to evaluate S-004992 in patients with tuberculosis,null,null,null,null,348025,null,Recruiting
null,Phase 4 Clinical,C4,levofloxacin,3492,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,20,Pharmacokinetic study and safety of levofloxacin in pediatric tuberculosis treatment,null,2021-08-31 12:00:00,2021-05-31 00:00:00,2021-05-31 00:00:00,381490,2019-05-12 00:00:00,Recruiting
null,Phase 4 Clinical,C4,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,100,"MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis",2008-04-01 00:00:00,2009-10-19 12:00:00,null,2008-04-01 00:00:00,8644,2007-06-30 00:00:00,Completed
null,Phase 3 Clinical,C3,delamanid,16545,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,"Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin",null,2019-12-21 12:00:00,null,null,280651,2017-08-31 00:00:00,Terminated
null,Phase 2/Phase 3 Clinical,C23,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,238,Treatment Shortening of MDR-TB Using Existing and New Drugs,null,2018-05-22 12:00:00,2021-06-30 00:00:00,2021-06-30 00:00:00,247456,2016-01-31 00:00:00,Recruiting
null,Phase 1 Clinical,C1,levofloxacin,3492,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,44,"A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin",null,2002-01-07 06:30:00,null,null,8780,1999-11-01 18:30:00,Completed
null,Phase 3 Clinical,C3,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB",null,2022-05-22 12:00:00,null,null,368916,2020-01-31 00:00:00,Terminated
null,Phase 4 Clinical,C4,Infanrix,6229,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,28,A Study of the Interaction Between BCG And MenC Immunization,2018-06-27 00:00:00,2016-08-01 00:00:00,null,2018-06-27 00:00:00,162886,2014-06-20 00:00:00,Completed
null,Phase 3 Clinical,C3,"clofazimine (oral, tuberculosis), Novartis",91861,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,750,Evaluating Newly Approved Drugs for Multidrug-resistant TB,null,2019-04-02 00:00:00,2021-04-30 00:00:00,2021-04-30 00:00:00,259506,2016-12-31 00:00:00,Recruiting
null,Phase 3 Clinical,C3,"clofazimine (oral, tuberculosis), Novartis",91861,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB",null,2022-05-22 12:00:00,null,null,368916,2020-01-31 00:00:00,Terminated
null,Phase 2 Clinical,C2,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,110,"Safety and Immunogenicity of Two Formulations of Tuberculosis Vaccines GSK-692342 Given at 0, 1 Months to Healthy Adults",2007-03-31 00:00:00,2009-03-21 12:00:00,null,2007-03-31 00:00:00,9520,2006-11-30 00:00:00,Completed
null,Phase 2 Clinical,C2,faropenem,4492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,45,Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers,null,2021-03-21 12:00:00,2019-05-30 00:00:00,2019-05-30 00:00:00,360329,2018-11-30 00:00:00,Not yet recruiting
null,Phase 4 Clinical,C4,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 3 Clinical,C3,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,180,"Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB",null,2020-02-20 12:00:00,2022-01-31 00:00:00,2022-01-31 00:00:00,293734,2017-10-31 00:00:00,Recruiting
null,Phase 1/Phase 2 Clinical,C12,"clofazimine (oral, tuberculosis), Novartis",91861,Efficacy,Mycobacterium tuberculosis infection,221,N,250,Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis,null,2021-07-31 00:00:00,null,null,374838,2019-05-01 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,488,NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB,null,2020-11-24 12:00:00,2024-08-04 00:00:00,2024-08-04 00:00:00,348056,2018-08-05 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,14,A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA-85A Vaccine in Healthy Volunteers,2003-10-31 00:00:00,2005-01-19 12:00:00,2003-07-31 00:00:00,2003-10-31 00:00:00,9320,2002-09-30 00:00:00,Completed
null,Phase 3 Clinical,C3,clarithromycin,2829,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,500,The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB,null,2021-06-27 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,369109,2019-03-08 00:00:00,Recruiting
European Ancestry,Phase 1 Clinical,C1,VPM-1002,55569,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,80,Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Healthy Male Volunteers,2009-12-31 00:00:00,2011-01-20 12:00:00,null,2009-12-31 00:00:00,48943,2008-09-30 00:00:00,Completed
null,Phase 1 Clinical,C1,sutezolid,11088,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,19,"Safety, Tolerability And Pharmacokinetics Study Of Single-Doses Of PNU-100480 In Healthy Adults",2009-08-31 00:00:00,2011-08-20 12:00:00,null,2009-08-31 00:00:00,50188,2009-04-30 00:00:00,Completed
null,Phase 4 Clinical,C4,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,827,"An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis",2012-11-30 00:00:00,2010-12-05 12:00:00,null,2012-11-30 00:00:00,153990,2008-08-15 00:00:00,Completed
null,Phase 2 Clinical,C2,levofloxacin,3492,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,101,Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB,null,2017-05-22 12:00:00,2020-03-31 00:00:00,2020-03-31 00:00:00,149562,2015-01-31 00:00:00,No longer recruiting
null,Phase not specified,NS,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,null,Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen,null,2003-09-07 12:00:00,null,null,10648,2001-07-02 00:00:00,Recruiting
null,Phase 3 Clinical,C3,emtricitabine,4728,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,240,"Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone",2017-04-30 00:00:00,2015-12-20 12:00:00,null,2017-04-30 00:00:00,150793,2013-08-30 00:00:00,Completed
null,Phase 4 Clinical,C4,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,130,Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg,2012-10-31 00:00:00,2009-04-07 12:00:00,null,2012-10-31 00:00:00,11181,2007-01-31 00:00:00,Terminated
null,Phase not specified,NS,moxifloxacin,12978,"Bioequivalence,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,18,"An Open-Label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Haynemoks, 400 mg (Hayglans Laboratories Pvt. Ltd., India) and Avelox, 400 mg (Bayer Healthcare AG, Germany) in Healthy Volunteers",null,2014-05-02 00:00:00,2013-07-05 00:00:00,2013-07-05 00:00:00,168898,2012-10-29 00:00:00,Status not specified
null,Phase 2 Clinical,C2,Tritanrix HB,12862,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,302,Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants,2012-03-31 00:00:00,2012-11-19 12:00:00,null,2012-03-31 00:00:00,65639,2010-07-31 00:00:00,Completed
null,Phase 2 Clinical,C2,AERAS-402,53975,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,26,"Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults",2012-05-31 00:00:00,2012-04-21 12:00:00,null,2012-05-31 00:00:00,62096,2009-12-31 00:00:00,Completed
null,Phase 3 Clinical,C3,gatifloxacin,7017,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1836,A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis,null,2007-05-23 12:00:00,null,null,10855,2005-01-31 00:00:00,Recruiting
null,Phase 1 Clinical,C1,rifapentine,15102,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,44,Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single-Dose or in Divided Doses to Healthy Adults,2013-06-30 00:00:00,2014-09-30 00:00:00,null,2013-06-30 00:00:00,86389,2012-06-30 00:00:00,Terminated
African Ancestry,Phase 3 Clinical,C3,rifabutin,4229,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,50,"A single-blind, randomized, safety study comparing rifabutin with rifampicin in the treatment of HIV-1-associated tuberculosis",null,1998-04-21 12:00:00,null,null,15878,1995-12-31 00:00:00,Status not specified
null,Phase 2 Clinical,C2,pretomanid,13323,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,65,Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With,2011-08-31 00:00:00,2013-02-19 12:00:00,null,2011-08-31 00:00:00,71107,2010-10-31 00:00:00,Completed
null,Phase 1 Clinical,C1,"ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis",68617,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,60,Phase I ID-93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers,2014-05-31 00:00:00,2014-12-21 12:00:00,null,2014-05-31 00:00:00,87507,2012-08-31 00:00:00,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,24,"Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Intramuscular Route and the Intradermal Route",2011-01-01 00:00:00,2012-05-22 12:00:00,null,2011-01-01 00:00:00,69212,2010-01-31 00:00:00,Completed
null,Phase 1 Clinical,C1,lopinavir + ritonavir,14681,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,52,"Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin",2013-05-31 00:00:00,2014-09-20 12:00:00,null,2013-05-31 00:00:00,86312,2012-05-31 00:00:00,Completed
null,Phase 2 Clinical,C2,golotimod,25023,Efficacy,Mycobacterium tuberculosis infection,221,N,44,Phase II Trial of SCV-07 in TB,null,null,null,null,144312,null,Completed
null,Phase 4 Clinical,C4,"rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals",69440,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,100,"Comparison of Sputum Conversion Rates, Plasma Rifampicin Levels and Cyp 450 Activity Pulmonary Tuberculosis Patients Have Received 8 Weeks of Intensive Phase Therapy With Standard Dose Regimen Versus Risorine Kit",null,2014-09-30 12:00:00,null,null,142231,2012-06-10 00:00:00,Recruiting
null,Phase 4 Clinical,C4,"rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals",69440,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,50,A Risorine Study in Sputum Positive Patients After 8 Weeks of Conventional Treatment,null,2014-09-30 12:00:00,null,null,138715,2012-06-10 00:00:00,Recruiting
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,350,TBTC Study 27: Moxifloxacin versus Ethambutol for TB Treatment,2005-12-31 00:00:00,2005-11-19 12:00:00,null,2005-12-31 00:00:00,10684,2003-07-31 00:00:00,Completed
null,Phase 1 Clinical,C1,efavirenz,10172,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,52,"Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin",2013-05-31 00:00:00,2014-09-20 12:00:00,null,2013-05-31 00:00:00,86312,2012-05-31 00:00:00,Completed
null,Phase not specified,NS,lamivudine,3474,"Safety,Efficacy,Bioavailability",Mycobacterium tuberculosis infection,221,N,120,"Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression",null,2008-08-03 12:00:00,null,null,136052,2006-05-29 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,70,"Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis",2007-12-31 00:00:00,2006-06-20 12:00:00,null,2007-12-31 00:00:00,10869,2004-02-29 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,stavudine,4481,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,570,Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients,2011-04-30 00:00:00,2010-03-07 12:00:00,2011-03-31 00:00:00,2011-04-30 00:00:00,10948,2007-12-31 00:00:00,Completed
null,Phase not specified,NS,omeprazole,44305,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,13,The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity,2011-06-30 00:00:00,2012-10-20 12:00:00,null,2011-06-30 00:00:00,122291,2010-07-01 00:00:00,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,24,"Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Aerosol Route and the Intradermal Route",2013-04-01 00:00:00,2014-01-19 12:00:00,null,2013-04-01 00:00:00,83464,2011-09-30 00:00:00,Completed
null,Phase 2a Clinical,C2A,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,48,"A phase IIa, open-label, safety and immunogenicity study of MVA-85A in HIV- and/or Mycobacterium tuberculosis-infected adults",null,2013-12-15 12:00:00,null,null,86807,2011-08-26 00:00:00,Status not specified
null,Phase not specified,NS,rifabutin,4229,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,39,"An open-label, comparative, multicenter trial to evaluate long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis",null,2005-06-19 12:00:00,null,null,113726,2003-02-28 00:00:00,Status not specified
null,Phase not specified,NS,IMM-201,11115,Efficacy,Mycobacterium tuberculosis infection,221,N,204,"A Randomized, Double-blind, Multicenter, Placebo-controlled Trial to Study the Efficacy of Mycobacterium vaccae Immunotherapy for Tuberculosis in KwaZulu, South Africa, 1991-97",null,2003-02-20 12:00:00,null,null,109626,2000-10-31 00:00:00,Status not specified
null,Phase 3 Clinical,C3,Actimmune,3365,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,A phase III study to evaluate the safety and efficacy of aerosolized Actimmune for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB) in patients who have failed a treatment regimen of anti-tuberculosis therapy,null,2002-11-21 12:00:00,null,null,14945,2000-08-01 00:00:00,Status not specified
null,Phase 2b Clinical,C2B,delamanid,16545,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,481,"A Placebo-Controlled, Phase II Trial to Evaluate OPC-67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-Resistant Tuberculosis (TB)",2010-10-31 00:00:00,2010-08-20 12:00:00,null,2010-10-31 00:00:00,15754,2008-04-30 00:00:00,Completed
null,Phase 4 Clinical,C4,tenofovir disoproxil fumarate,14493,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,200,RIFART,2011-04-19 00:00:00,2007-05-21 12:00:00,null,2011-04-19 00:00:00,131240,2005-03-15 00:00:00,Terminated
null,Phase 3 Clinical,C3,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,493,Optimization of Tuberculosis and HIV Co-treatment in Africa,null,2010-03-16 12:00:00,null,null,131419,2008-01-09 00:00:00,Recruiting
null,Phase 1/Phase 2 Clinical,C12,linezolid,11036,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,70,"Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis",2007-12-31 00:00:00,2006-06-20 12:00:00,null,2007-12-31 00:00:00,10869,2004-02-29 00:00:00,Completed
null,Phase not specified,NS,Glutoxim,28379,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,42,Glutoxim in the Complex Treatment of Tuberculosis,2002-01-01 00:00:00,null,null,2002-01-01 00:00:00,149460,null,Completed
null,Phase 1 Clinical,C1,TB/FLU-04L,98373,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,36,"Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine",2015-02-28 00:00:00,2016-02-20 12:00:00,null,2015-02-28 00:00:00,235054,2013-10-31 00:00:00,Completed
null,Phase 3 Clinical,C3,nevirapine,3700,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,145,Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin,2010-12-31 00:00:00,2009-04-07 12:00:00,null,2010-12-31 00:00:00,10947,2007-01-31 00:00:00,Completed
null,Phase 1 Clinical,C1,linezolid,11036,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,59,"Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers",2010-05-31 00:00:00,2012-02-20 12:00:00,null,2010-05-31 00:00:00,60906,2009-10-31 00:00:00,Completed
null,Phase 3 Clinical,C3,gatifloxacin,7017,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,416,"Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB",null,2006-09-03 12:00:00,null,null,150332,2004-05-14 00:00:00,Terminated
null,Phase 4 Clinical,C4,ribavirin,5369,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,550,"Antivirus Therapy for Population with HIV, HCV and TB Co-infection Clinical Trial",null,2011-05-31 00:00:00,null,null,162528,2009-05-01 00:00:00,Recruiting
null,Phase 3 Clinical,C3,lamivudine,3474,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,145,Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin,2010-12-31 00:00:00,2009-04-07 12:00:00,null,2010-12-31 00:00:00,10947,2007-01-31 00:00:00,Completed
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,75,Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC-207 in Treatment of Pulmonary Tuberculosis,2008-08-01 00:00:00,null,null,2008-08-01 00:00:00,150059,null,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,30,Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults,2014-12-31 00:00:00,2015-11-20 12:00:00,null,2014-12-31 00:00:00,142322,2013-07-31 00:00:00,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,37,"Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA-85A, as a Way to Increase Immune Response and Avoid Anti-Vector Immunity",2015-02-02 00:00:00,2016-02-20 12:00:00,null,2015-02-02 00:00:00,156675,2013-10-31 00:00:00,Completed
null,Phase not specified,NS,"tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences",49219,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,63,Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment,2011-02-28 00:00:00,2010-06-30 00:00:00,2011-12-31 00:00:00,2011-02-28 00:00:00,169697,2008-03-31 00:00:00,Terminated
null,Phase 3 Clinical,C3,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1650,A Clinical Trial to Study the Effectiveness and Safety of 3- and 4-Month Regimens as Compared to the Standard 6-Month Regimen for the Treatment of Infectious Pulmonary Tuberculosis Patients,null,2009-09-18 12:00:00,null,null,121916,2007-05-30 00:00:00,Recruiting
null,Phase 3 Clinical,C3,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,3000,Brief Rifapentine-Isoniazid Evaluation for TB Prevention,2017-11-14 00:00:00,2014-09-12 12:00:00,null,2017-11-14 00:00:00,79741,2012-05-23 00:00:00,Completed
null,Phase 2 Clinical,C2,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,45,Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-Endemic Region,2008-12-31 00:00:00,2010-06-20 12:00:00,null,2008-12-31 00:00:00,11563,2008-02-29 00:00:00,Completed
null,Phase 2 Clinical,C2,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,60,Safety and Immunogenicity of a Candidate Tuberculosis Vaccine in Healthy HIV Negative Adolescents,2010-09-30 00:00:00,2012-04-21 12:00:00,null,2010-09-30 00:00:00,59304,2009-12-31 00:00:00,Completed
null,Phase not specified,NS,moxifloxacin,12978,Efficacy,Mycobacterium tuberculosis infection,221,N,43,"A comparative, open-labeled, randomized study to evaluate the bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis",null,2006-03-22 12:00:00,null,null,114922,2003-12-01 00:00:00,Status not specified
null,Phase 4 Clinical,C4,lamivudine,3474,Safety,Mycobacterium tuberculosis infection,221,N,156,Appropriate Timing of HAART in Co-infected HIV/TB Patients,2011-05-31 00:00:00,2012-03-31 00:00:00,2013-10-31 00:00:00,2011-05-31 00:00:00,61991,2009-10-31 00:00:00,Terminated
null,Phase 4 Clinical,C4,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,3738,Intervention study in rural residents (50 to 70 years old) with latent Mycobacterium tuberculosis infection,null,2016-04-22 12:00:00,2016-12-31 00:00:00,2016-12-31 00:00:00,243294,2014-01-01 00:00:00,No longer recruiting
null,Phase 3 Clinical,C3,AEC/BC02,81363,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,null,A Phase III trial of recombinant tuberculosis vaccine AEC/BC02 in patients with tuberculosis,2018-09-03 00:00:00,null,null,2018-09-03 00:00:00,352354,null,Completed
null,Phase 4 Clinical,C4,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1002,Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT,2014-10-31 00:00:00,2015-01-20 12:00:00,null,2014-10-31 00:00:00,177457,2012-09-30 00:00:00,Completed
null,Phase 1 Clinical,C1,Perchlozone,87251,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,40,"An open, phase I study to study the pharmacokinetics, safety and tolerability of Perhlozone (400 mg capsules) in healthy volunteers after a single dose",null,2014-07-10 12:00:00,2013-01-13 00:00:00,2013-01-13 00:00:00,167779,2012-03-20 00:00:00,Status not specified
null,Phase 4 Clinical,C4,sutezolid,11088,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
African Ancestry,Phase not specified,NS,"artesunate + amodiaquine combination tablet (malaria), DNDi/sanofi-aventis",53041,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,36,Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients,null,2015-01-31 00:00:00,2014-01-31 00:00:00,2014-01-31 00:00:00,142485,2013-01-31 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,"rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer",89460,"Safety,Bioequivalence,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,28,"A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, RIN-150 And Individual Reference Drugs In Healthy Volunteers",2012-10-31 00:00:00,2015-01-20 12:00:00,null,2012-10-31 00:00:00,164292,2012-09-30 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,rifapentine,15102,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,60,"Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients",null,2020-03-25 12:00:00,2018-11-03 00:00:00,2018-11-03 00:00:00,329251,2018-01-18 00:00:00,Recruiting
null,Phase 1 Clinical,C1,TBA-354,71742,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,18,"A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects",null,2018-03-21 12:00:00,null,null,246089,2015-11-30 00:00:00,Terminated
Japanese Ancestry,Phase 2 Clinical,C2,levofloxacin,3492,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,6,An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB),2018-11-08 00:00:00,2017-05-20 00:00:00,null,2018-11-08 00:00:00,222400,2015-02-18 00:00:00,Completed
null,Phase 1 Clinical,C1,"ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis",68617,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,36,Phase I Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent,null,2021-07-22 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,366672,2019-04-02 00:00:00,Recruiting
null,Phase 2a Clinical,C2A,"amoxicillin + clavulanate potassium, GSK",44284,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,88,Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB,null,2019-12-13 12:00:00,2022-07-31 00:00:00,2022-07-31 00:00:00,300655,2017-08-23 00:00:00,Recruiting
null,Phase 3 Clinical,C3,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,109,A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis,null,2017-06-30 00:00:00,2021-10-31 00:00:00,2021-10-31 00:00:00,219499,2015-03-31 00:00:00,No longer recruiting
null,Phase 2b Clinical,C2B,metformin hydrochloride,6050,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,316,Metformin in tuberculosis,null,2021-02-20 12:00:00,null,null,325158,2018-11-01 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,530,The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB,null,2018-08-20 12:00:00,2022-06-30 00:00:00,2022-06-30 00:00:00,228190,2016-04-30 00:00:00,Recruiting
null,Phase 2b Clinical,C2B,dolutegravir,59062,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,120,Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy,null,2021-09-28 00:00:00,2021-01-31 00:00:00,2021-01-31 00:00:00,384080,2019-04-30 00:00:00,Recruiting
null,Phase 2a Clinical,C2A,RUTI,57308,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,27,Safety of RUTI Vaccination in MDR-TB Patients,null,2021-04-02 00:00:00,2020-07-31 00:00:00,2020-07-31 00:00:00,256039,2019-01-01 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,84,"Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis",null,2019-01-30 00:00:00,2021-01-15 00:00:00,2021-01-15 00:00:00,243619,2016-08-31 00:00:00,No longer recruiting
null,Phase 2/Phase 3 Clinical,C23,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,630,Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s),null,2019-05-23 12:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,244304,2017-01-31 00:00:00,Recruiting
null,Phase 2 Clinical,C2,faropenem,4492,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,45,Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers,null,2021-04-21 12:00:00,2019-04-30 00:00:00,2019-04-30 00:00:00,224111,2018-12-31 00:00:00,Not yet recruiting
null,Phase 2b Clinical,C2B,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,120,Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy,null,2021-09-28 00:00:00,2021-01-31 00:00:00,2021-01-31 00:00:00,384080,2019-04-30 00:00:00,Recruiting
null,Phase 1/Phase 2 Clinical,C12,bedaquiline,51310,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,72,"Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis",null,2019-12-08 12:00:00,2022-01-31 00:00:00,2022-01-31 00:00:00,272021,2017-08-18 00:00:00,Recruiting
null,Phase 3 Clinical,C3,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,"Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin",null,2019-12-21 12:00:00,null,null,280651,2017-08-31 00:00:00,Terminated
null,Phase 2/Phase 3 Clinical,C23,ceftriaxone,44384,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,624,Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia,null,2022-07-02 00:00:00,2024-01-31 00:00:00,2024-01-31 00:00:00,377163,2020-01-01 00:00:00,Not yet recruiting
null,Phase 2/Phase 3 Clinical,C23,valganciclovir,25182,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,624,Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia,null,2022-07-02 00:00:00,2024-01-31 00:00:00,2024-01-31 00:00:00,377163,2020-01-01 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,750,Evaluating Newly Approved Drugs for Multidrug-resistant TB,null,2019-04-02 00:00:00,2021-04-30 00:00:00,2021-04-30 00:00:00,259506,2016-12-31 00:00:00,Recruiting
null,Phase 1/Phase 2 Clinical,C12,tenofovir disoproxil fumarate,14493,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,60,"Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients",null,2020-03-25 12:00:00,2018-11-03 00:00:00,2018-11-03 00:00:00,329251,2018-01-18 00:00:00,Recruiting
null,Phase 4 Clinical,C4,"clofazimine (oral, tuberculosis), Novartis",91861,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,140,"Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis",null,2012-03-22 12:00:00,2010-12-31 00:00:00,2010-12-31 00:00:00,328802,2009-12-01 00:00:00,No longer recruiting
null,Phase 2/Phase 3 Clinical,C23,"clofazimine (oral, tuberculosis), Novartis",91861,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,630,Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s),null,2019-05-23 12:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,244304,2017-01-31 00:00:00,Recruiting
null,Phase 4 Clinical,C4,"clofazimine (oral, tuberculosis), Novartis",91861,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,144,"A randomized, multicenter, controlled trial for clofazimine-containing protocol in the treatment of newly diagnosed multidrug-resistant tuberculosis",null,2015-03-23 12:00:00,2015-06-30 00:00:00,2015-06-30 00:00:00,365020,2012-12-01 00:00:00,No longer recruiting
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,165,Study on Tuberculosis Resistant to Treatment,null,2021-05-23 12:00:00,null,null,369747,2019-02-01 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,"clofazimine (oral, tuberculosis), Novartis",91861,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,102,Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC),null,2019-08-01 12:00:00,2021-08-31 00:00:00,2021-08-31 00:00:00,279727,2017-04-11 00:00:00,Recruiting
null,Phase 2 Clinical,C2,linezolid,11036,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,165,Study on Tuberculosis Resistant to Treatment,null,2021-05-23 12:00:00,null,null,369747,2019-02-01 00:00:00,Not yet recruiting
null,Phase 2/Phase 3 Clinical,C23,linezolid,11036,Efficacy,Mycobacterium tuberculosis infection,221,N,54,Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial,null,2021-10-20 12:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,379769,2019-07-01 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,zidovudine,44316,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,230,Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis,null,2020-08-28 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,334027,2018-04-15 00:00:00,Recruiting
null,Phase 3 Clinical,C3,ESAT-6CFP10,95442,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,1090,Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen,2018-03-31 00:00:00,2018-04-21 12:00:00,null,2018-03-31 00:00:00,247763,2015-12-31 00:00:00,Completed
null,Phase not specified,NS,clarithromycin,2829,Efficacy,Mycobacterium tuberculosis infection,221,N,null,The research of new regimen for multidrug-resistant tuberculosis treatment,null,2011-01-21 12:00:00,2010-12-31 00:00:00,2010-12-31 00:00:00,244777,2008-10-01 00:00:00,No longer recruiting
null,Phase 1 Clinical,C1,dolutegravir,59062,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,75,Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers,null,2018-08-09 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,260814,2016-06-03 00:00:00,Recruiting
null,Phase 2 Clinical,C2,dolutegravir,59062,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,108,Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis,null,2021-09-29 00:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,371202,2019-05-01 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,rifapentine,15102,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,11,"Doravirine, Rifapentine and Isoniazid Interaction",null,2021-07-05 12:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,374387,2019-04-30 00:00:00,Recruiting
null,Phase 1/Phase 2 Clinical,C12,emtricitabine,4728,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,60,"Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients",null,2020-03-25 12:00:00,2018-11-03 00:00:00,2018-11-03 00:00:00,329251,2018-01-18 00:00:00,Recruiting
null,Phase 4 Clinical,C4,clarithromycin,2829,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,7,Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients,2012-11-30 00:00:00,2014-04-01 00:00:00,null,2012-11-30 00:00:00,182646,2011-12-31 00:00:00,Completed
null,Phase not specified,NS,"interferon gamma follow-on biologic, PHARMACLON LLC",81264,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,90,"Randomized, comparative, controlled, open-label clinical study of efficacy and safety of Ingaron (recombinant human interferon gamma) production of ""NPP"" FARMAKLON, Russia in the treatment of patients with pulmonary tuberculosis",null,2016-09-14 12:00:00,2014-07-28 00:00:00,2014-07-28 00:00:00,194177,2014-05-26 00:00:00,Status not specified
Asian Ancestry,Phase not specified,NS,lamivudine,3474,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,400,Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China,null,2011-05-06 12:00:00,2013-06-30 00:00:00,2013-06-30 00:00:00,76946,2009-02-28 00:00:00,Recruiting
null,Phase 1 Clinical,C1,SQ-109,31010,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,10,Phase Ic Study of Safety and PK of SQ-109 300 mg Daily,2011-04-30 00:00:00,2013-03-21 12:00:00,null,2011-04-30 00:00:00,77682,2010-11-30 00:00:00,Completed
null,Phase 4 Clinical,C4,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,780,Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis,2010-07-31 00:00:00,2008-11-05 12:00:00,null,2010-07-31 00:00:00,10681,2006-08-31 00:00:00,Completed
null,Phase 3 Clinical,C3,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,116,Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment,null,2008-11-28 00:00:00,2011-12-31 00:00:00,2011-12-31 00:00:00,10863,2006-06-30 00:00:00,Suspended
null,Phase 4 Clinical,C4,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,5,A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV,2008-03-01 00:00:00,2009-10-05 12:00:00,2008-03-31 00:00:00,2008-03-01 00:00:00,11177,2007-07-31 00:00:00,Terminated
null,Phase 2 Clinical,C2,Prevnar,4144,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,302,Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants,2012-03-31 00:00:00,2012-11-19 12:00:00,null,2012-03-31 00:00:00,65639,2010-07-31 00:00:00,Completed
null,Phase 1 Clinical,C1,AERAS-402,53975,Safety,Mycobacterium tuberculosis infection,221,Y,null,"A phase I study to determine the safety of AERAS-402 in healthy adults, all of whom have been previously vaccinated with the Bacille Calmette-Guerin (BCG) vaccine and a subset of whom have evidence of having been exposed to tuberculosis",2009-11-03 00:00:00,2011-02-06 12:00:00,null,2009-11-03 00:00:00,59617,2008-10-17 00:00:00,Completed
Asian Ancestry,Phase 2 Clinical,C2,delpazolid,76307,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,64,"A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK",null,2019-04-01 12:00:00,2018-12-31 00:00:00,2018-12-31 00:00:00,265899,2016-12-10 00:00:00,Recruiting
null,Phase 2 Clinical,C2,rifabutin,4229,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,140,EARNEST Rifabutin Pharmacokinetics (PK) Substudy,2014-01-31 00:00:00,2014-10-02 00:00:00,null,2014-01-31 00:00:00,90175,2012-05-03 00:00:00,Completed
null,Phase 2 Clinical,C2,"tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck & Co",50038,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,30,Pharmacokinetics of Emtricitabine/Tenofovir + Efavirenz in HIV-Infected Patients With Tuberculosis,null,2011-02-05 12:00:00,2009-12-31 00:00:00,2009-12-31 00:00:00,10945,2008-11-30 00:00:00,Recruiting
null,Phase 2 Clinical,C2,pretomanid,13323,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,60,Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis,2010-05-31 00:00:00,2011-12-21 12:00:00,null,2010-05-31 00:00:00,59043,2009-08-31 00:00:00,Completed
null,Phase 2 Clinical,C2,"meningococcal C/CRM-197 conjugate vaccine, Chiron",3612,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,302,Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants,2012-03-31 00:00:00,2012-11-19 12:00:00,null,2012-03-31 00:00:00,65639,2010-07-31 00:00:00,Completed
null,Phase 2a Clinical,C2A,linezolid,11036,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,41,Linezolid to Treat Extensively-Drug Resistant Tuberculosis,2014-11-30 00:00:00,2010-10-31 00:00:00,null,2014-11-30 00:00:00,23143,2008-07-31 00:00:00,Completed
null,Phase 2 Clinical,C2,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,428,Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis,null,2016-05-22 12:00:00,2016-06-30 00:00:00,2016-06-30 00:00:00,161831,2014-01-31 00:00:00,Recruiting
null,Phase 4 Clinical,C4,"rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals",69440,Efficacy,Mycobacterium tuberculosis infection,221,N,144,Comparative Evaluation of the Effect of Risorine in Patients With Newly Diagnosed Sputum Smear Positive Pulmonary Tuberculosis,null,2013-06-01 12:00:00,null,null,118547,2011-02-10 00:00:00,Completed
null,Phase not specified,NS,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,65,"A Multicenter, Prospective, Randomized, Controlled Trial to Assess  the Efficacy and Safety of Linezolid for the Treatment of Extensively Drug Resistant Tuberculosis in China",null,null,null,null,183541,null,Completed
null,Phase 1 Clinical,C1,clindamycin,44370,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,62,Pharmacokinetics of Antistaphylococcal Antibiotics in Infants,2015-05-31 00:00:00,2015-04-08 12:00:00,null,2015-05-31 00:00:00,98566,2013-01-31 00:00:00,Completed
null,Phase 2 Clinical,C2,"thalidomide, Celgene",8050,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,50,"Phase II, Placebo-Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections",1999-06-01 00:00:00,1992-12-05 12:00:00,null,1999-06-01 00:00:00,92426,1990-09-30 00:00:00,Completed
null,Phase 2 Clinical,C2,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,248,Safety and Immunogenicity of MVA-85A Prime and Bacille Calmette-Guerin Boost Vaccination,2015-05-31 00:00:00,2015-01-06 12:00:00,null,2015-05-31 00:00:00,89833,2012-10-31 00:00:00,Completed
null,Phase 3 Clinical,C3,nevirapine,3700,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,355,"Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis",2011-04-30 00:00:00,2008-08-19 12:00:00,null,2011-04-30 00:00:00,161275,2006-04-30 00:00:00,Completed
null,Phase 2 Clinical,C2,tenofovir disoproxil fumarate,14493,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,155,Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis,2012-05-31 00:00:00,2011-12-30 00:00:00,null,2012-05-31 00:00:00,40948,2009-07-31 00:00:00,Completed
null,Phase 1 Clinical,C1,pretomanid,13323,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,52,"Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin",2013-05-31 00:00:00,2014-09-20 12:00:00,null,2013-05-31 00:00:00,86312,2012-05-31 00:00:00,Completed
null,Phase 1 Clinical,C1,AERAS-402,53975,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,40,Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A,2014-08-31 00:00:00,2015-01-20 12:00:00,null,2014-08-31 00:00:00,91280,2012-09-30 00:00:00,Completed
null,Phase 1 Clinical,C1,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,88,TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions,2011-04-30 00:00:00,2013-06-19 12:00:00,null,2011-04-30 00:00:00,74529,2011-02-28 00:00:00,Completed
null,Phase 4 Clinical,C4,Pentacel,15298,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,28,A Study of the Interaction Between BCG And MenC Immunization,2018-06-27 00:00:00,2016-08-01 00:00:00,null,2018-06-27 00:00:00,162886,2014-06-20 00:00:00,Completed
null,Phase 2 Clinical,C2,VPM-1002,55569,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,416,Study to Evaluate the Safety and Immunogenicity of VPM-1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa,2017-11-30 00:00:00,2017-10-19 12:00:00,null,2017-11-30 00:00:00,224781,2015-06-30 00:00:00,Completed
null,Phase not specified,NS,interferon alfa-2b,45998,Efficacy,Mycobacterium tuberculosis infection,221,N,70,Interferon Alpha-2b in the Complex Therapy of Patients With Pulmonary Tuberculosis Concurrent With Broncho-obstructive Syndrome,2009-01-01 00:00:00,2009-04-22 12:00:00,null,2009-01-01 00:00:00,149989,2007-01-01 00:00:00,Completed
null,Phase 2 Clinical,C2,rifapentine,15102,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,230,Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection,2008-08-31 00:00:00,2008-01-20 12:00:00,null,2008-08-31 00:00:00,10687,2005-09-30 00:00:00,Completed
null,Phase not specified,NS,rifabutin,4229,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,null,Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen,null,2003-09-07 12:00:00,null,null,10648,2001-07-02 00:00:00,Recruiting
null,Phase 2a Clinical,C2A,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,60,"An Open-Label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Doses (md) of TMC-207 Oral Solution (Os) and Isoniazid (JH), TMC-207 Os and Pyrazinamide (JZ), TMC-207 Os and Rifampin (JR) or TMC-207 Os and Isoniazid and Pyrazinamide (JHZ), Compared to the three Principle Drugs of Standard Anti-Tuberculosis Treatment (HRZ) in Treatment-Naive Subjects With Sputum-Smear Positive Pulmonary Tuberculosis",null,2007-10-15 12:00:00,null,null,131253,2005-06-25 00:00:00,Recruiting
null,Phase 2 Clinical,C2,nevirapine,3700,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,47,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam,2012-09-30 00:00:00,2012-10-19 12:00:00,null,2012-09-30 00:00:00,11188,2010-06-30 00:00:00,Completed
null,Phase 3 Clinical,C3,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,240,"Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone",2017-04-30 00:00:00,2015-12-20 12:00:00,null,2017-04-30 00:00:00,150793,2013-08-30 00:00:00,Completed
null,Phase 2 Clinical,C2,rifapentine,15102,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,35,Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine,2003-05-31 00:00:00,2002-07-21 12:00:00,2001-05-31 00:00:00,2003-05-31 00:00:00,10655,2000-03-31 00:00:00,Completed
null,Phase 1 Clinical,C1,stavudine,4481,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,44,Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis,null,2002-05-02 12:00:00,null,null,10646,2000-02-25 00:00:00,Completed
null,Phase not specified,NS,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,86,A study to evaluate the safety and efficacy of moxifloxacin in comparision with cephalexin in patients being treated for uncomplicated skin and soft tissue infections,null,2002-04-21 12:00:00,null,null,16244,1999-12-31 00:00:00,Status not specified
null,Phase not specified,NS,gatifloxacin,7017,Efficacy,Mycobacterium tuberculosis infection,221,N,217,"A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)",null,2007-03-17 12:00:00,2006-01-01 00:00:00,2006-01-01 00:00:00,152200,2004-11-25 00:00:00,Completed
null,Phase 2 Clinical,C2,delamanid,16545,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,37,"A 6-Month Safety, Efficacy and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis",null,2015-11-09 12:00:00,2020-02-29 00:00:00,2020-02-29 00:00:00,133567,2013-07-20 00:00:00,No longer recruiting
null,Phase not specified,NS,bedaquiline,51310,Efficacy,Mycobacterium tuberculosis infection,221,N,68,"A randomized, double-blinded, dose-ranging study to assess the 14-day early bactericidal activity of bedaquiline (TMC-207) in patients with sputum microscopy smear-positive pulmonary tuberculosis",null,2015-06-24 12:00:00,null,null,139369,2013-03-04 00:00:00,Status not specified
null,Phase not specified,NS,"ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88505,"Bioequivalence,Bioavailability",Mycobacterium tuberculosis infection,221,Y,24,Ethylamine pyrazine Lifestyle Isonicotinic piece IV bioequivalence trials,null,2016-03-21 12:00:00,null,null,177165,2013-11-30 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,tenofovir disoproxil fumarate,14493,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,240,"Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone",2017-04-30 00:00:00,2015-12-20 12:00:00,null,2017-04-30 00:00:00,150793,2013-08-30 00:00:00,Completed
null,Phase 1 Clinical,C1,ChAdOx1-85A,84564,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,42,Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults,2016-04-30 00:00:00,2015-11-20 12:00:00,null,2016-04-30 00:00:00,120744,2013-07-31 00:00:00,Completed
null,Phase 3 Clinical,C3,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,355,"Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis",2011-04-30 00:00:00,2008-08-19 12:00:00,null,2011-04-30 00:00:00,161275,2006-04-30 00:00:00,Completed
null,Phase not specified,NS,bedaquiline,51310,"Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,null,A Bioavailability Study of Two New Formulations of Bedaquiline on Pediatric Populaion,null,2016-04-04 12:00:00,null,null,163991,2013-12-14 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,Safety,Mycobacterium tuberculosis infection,221,N,20,"A phase I study to evaluate the safety and immunogenicity of a novel, proprietary prophylactic vaccine MTB72F to induce protection against tuberculosis (TB)",null,2006-06-28 12:00:00,null,null,9554,2004-03-08 00:00:00,Status not specified
null,Phase 3 Clinical,C3,cadi-05,55173,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1020,Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients,2011-03-31 00:00:00,2007-07-21 12:00:00,null,2011-03-31 00:00:00,10057,2005-03-31 00:00:00,Completed
null,Phase 3 Clinical,C3,didanosine,2935,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,642,A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients,2010-07-31 00:00:00,2007-09-05 12:00:00,null,2010-07-31 00:00:00,201474,2005-06-30 00:00:00,Completed
null,Phase 1 Clinical,C1,rifapentine,15102,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,32,Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects,2010-05-31 00:00:00,2012-06-30 00:00:00,null,2010-05-31 00:00:00,208141,2010-03-31 00:00:00,Completed
null,Phase 3 Clinical,C3,rifapentine,15102,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,60,Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis,null,2018-09-19 12:00:00,2020-03-31 00:00:00,2020-03-31 00:00:00,242269,2016-05-30 00:00:00,Recruiting
null,Phase 2 Clinical,C2,GamTBvac,107803,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,180,Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac,null,2021-03-22 12:00:00,2020-03-31 00:00:00,2020-03-31 00:00:00,373676,2018-12-01 00:00:00,Recruiting
null,Phase 2/Phase 3 Clinical,C23,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,3400,"Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI",null,2021-11-19 12:00:00,2023-12-31 00:00:00,2023-12-31 00:00:00,333384,2019-07-31 00:00:00,Not yet recruiting
null,Phase 4 Clinical,C4,rifapentine,15102,Efficacy,Mycobacterium tuberculosis infection,221,N,1500,"Latent Mycobacterium tuberculosis infection treatment among individuals with a history of prior tuberculosis: a randomized, controlled trial",null,2020-12-21 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,352729,2018-09-01 00:00:00,Recruiting
null,Phase 2b Clinical,C2B,sutezolid,11088,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,75,PanACEA Sutezolid Dose-finding and Combination Evaluation,null,2021-12-20 12:00:00,2020-02-29 00:00:00,2020-02-29 00:00:00,381674,2019-08-31 00:00:00,Not yet recruiting
null,Phase 2b Clinical,C2B,midazolam hydrochloride,44303,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,75,PanACEA Sutezolid Dose-finding and Combination Evaluation,null,2021-12-20 12:00:00,2020-02-29 00:00:00,2020-02-29 00:00:00,381674,2019-08-31 00:00:00,Not yet recruiting
null,Phase not specified,NS,didanosine,2935,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,592,Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings,null,2011-11-06 12:00:00,null,null,8820,2009-08-31 00:00:00,Completed
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,131,A clinical trial to study the effects of moxifloxacin with regular anti-tuberculosis drugs in Tuberculosis patients,null,2017-12-29 12:00:00,null,null,255644,2015-09-09 00:00:00,Recruiting
null,Phase 4 Clinical,C4,"superboosted lopinavir + ritonavir (pediatric oral formulation, HIV infection), DNDi",105321,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,96,Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB,2016-12-31 00:00:00,2015-04-08 12:00:00,null,2016-12-31 00:00:00,220686,2013-01-31 00:00:00,Completed
null,Phase 1 Clinical,C1,S-004992,61340,Safety,Mycobacterium tuberculosis infection,221,N,null,A phase I trial of S-004992 for the potential treatment of drug-resistant tuberculosis,null,null,null,null,334482,null,Planned
null,Phase not specified,NS,rifabutin,4229,Efficacy,Mycobacterium tuberculosis infection,221,N,null,The research of new regimen for multidrug-resistant tuberculosis treatment,null,2011-01-21 12:00:00,2010-12-31 00:00:00,2010-12-31 00:00:00,244777,2008-10-01 00:00:00,No longer recruiting
null,Phase 1/Phase 2 Clinical,C12,MTBVAC,89744,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,54,"Dose-escalation, Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults",null,2018-01-19 12:00:00,null,null,257534,2015-09-30 00:00:00,Completed
null,Phase 3 Clinical,C3,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB",null,2022-05-22 12:00:00,null,null,368916,2020-01-31 00:00:00,Terminated
null,Phase 3 Clinical,C3,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,460,Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis,null,2018-02-28 00:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,214156,2015-09-30 00:00:00,Recruiting
null,Phase 4 Clinical,C4,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,140,"Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis",null,2012-03-22 12:00:00,2010-12-31 00:00:00,2010-12-31 00:00:00,328802,2009-12-01 00:00:00,No longer recruiting
null,Phase 2 Clinical,C2,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,230,Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis,null,2020-08-28 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,334027,2018-04-15 00:00:00,Recruiting
null,Phase 2/Phase 3 Clinical,C23,levofloxacin,3492,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,900,A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis,null,2020-07-10 12:00:00,2022-03-12 00:00:00,2022-03-12 00:00:00,333435,2018-03-21 00:00:00,Recruiting
null,Phase 2a Clinical,C2A,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,75,TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis,2005-10-01 00:00:00,2007-09-20 12:00:00,2005-10-31 00:00:00,2005-10-01 00:00:00,9315,2005-05-31 00:00:00,Completed
null,Phase 3 Clinical,C3,GC-3107,108779,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,750,A Study of GC-3107(BCG Vaccine) in Healthy Infants,null,2021-09-20 12:00:00,2020-06-30 00:00:00,2020-06-30 00:00:00,380364,2019-06-01 00:00:00,Not yet recruiting
null,Phase not specified,NS,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,156,A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiological Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients,1998-10-31 00:00:00,2001-01-05 12:00:00,null,1998-10-31 00:00:00,8776,1998-10-31 00:00:00,Completed
null,Phase 3 Clinical,C3,moxifloxacin,12978,Efficacy,Mycobacterium tuberculosis infection,221,N,2500,Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349),null,2020-11-08 12:00:00,null,null,347338,2018-07-20 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,telacebec,85970,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,70,"Open, phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic parameters of Q-203 after single and multiple doses in healthy volunteers",null,2018-05-03 12:00:00,2016-11-30 00:00:00,2016-11-30 00:00:00,255234,2016-01-12 00:00:00,Status not specified
null,Phase 1/Phase 2 Clinical,C12,delamanid,16545,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,48,"Evaluating the Pharmacokinetics, Safety and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB",null,2020-05-21 12:00:00,2022-05-01 00:00:00,2022-05-01 00:00:00,297373,2018-01-30 00:00:00,Recruiting
null,Phase 3 Clinical,C3,VPM-1002,55569,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,12000,To Study Effect of Two Vaccines in Preventing Spread of Tuberculosis in Persons Living With New Tuberculosis Patients,null,2021-05-16 12:00:00,null,null,366261,2019-01-25 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,AERAS-402,53975,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,72,A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB,2010-11-30 00:00:00,2011-02-20 12:00:00,null,2010-11-30 00:00:00,226801,2008-10-31 00:00:00,Completed
null,Phase 3 Clinical,C3,pretomanid,13323,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,180,"Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB",null,2020-02-20 12:00:00,2022-01-31 00:00:00,2022-01-31 00:00:00,293734,2017-10-31 00:00:00,Recruiting
null,Phase 2/Phase 3 Clinical,C23,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,450,"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients",null,2020-11-18 12:00:00,2022-01-31 00:00:00,2022-01-31 00:00:00,319125,2018-07-30 00:00:00,Recruiting
null,Phase 1 Clinical,C1,AERAS-402,53975,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,32,"A phase I, double-blind, randomized, placebo-controlled, safety and immunogenicity study of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection",2009-08-11 00:00:00,2010-04-11 12:00:00,null,2009-08-11 00:00:00,8499,2007-12-21 00:00:00,Completed
null,Phase 3 Clinical,C3,azithromycin,2587,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1875,Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis,null,2021-06-16 12:00:00,2020-06-30 00:00:00,2020-06-30 00:00:00,341686,2019-02-25 00:00:00,Recruiting
null,Phase 1 Clinical,C1,"darunavir + cobicistat (fixed dose, HIV infection), Janssen R&D/ Gilead",72148,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,75,Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers,null,2018-08-09 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,260814,2016-06-03 00:00:00,Recruiting
null,Phase 2a Clinical,C2A,MTBVAC,89744,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,99,Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates,null,2021-06-02 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,340636,2019-02-11 00:00:00,Recruiting
null,Phase 2b Clinical,C2B,ESAT-6CFP10,95442,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,192,Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT-6-CFP-10,2015-07-31 00:00:00,2017-03-21 12:00:00,null,2015-07-31 00:00:00,219931,2014-11-30 00:00:00,Completed
null,Phase 1 Clinical,C1,TBI-223,107010,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,48,"A Phase 1 Study to Evaluate Safety, Tolerability, and PK of TBI-223 in Healthy Adults",null,2021-05-07 12:00:00,2019-10-01 00:00:00,2019-10-01 00:00:00,362067,2019-01-16 00:00:00,Recruiting
African Ancestry,Phase 1 Clinical,C1,pafuramidine,16755,Safety,Mycobacterium tuberculosis infection,221,N,175,"Randomized, double-blind, phase I safety and tolerability study of pafuramidine maleate (DB-289) in healthy subjects",2009-02-28 00:00:00,2009-11-29 00:00:00,2008-09-30 00:00:00,2009-02-28 00:00:00,17432,2007-11-30 00:00:00,Terminated
null,Phase 3 Clinical,C3,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,500,Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance,null,2021-09-29 00:00:00,2022-12-31 00:00:00,2022-12-31 00:00:00,375499,2019-06-30 00:00:00,Not yet recruiting
null,Phase 4 Clinical,C4,zileuton,4718,Efficacy,Mycobacterium tuberculosis infection,221,N,90,Optimization of Clinical Treatment Schemes for Multidrug - Resistant Pulmonary Tuberculosis Based on Host - Mediate,null,2019-02-09 12:00:00,2019-10-20 00:00:00,2019-10-20 00:00:00,276708,2016-10-20 00:00:00,Recruiting
null,Phase 2 Clinical,C2,"clofazimine (oral, tuberculosis), Novartis",91861,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,320,Evaluation of clofazimine as a part of TB treatment in order to shorten the duration of treatment,null,2021-07-21 12:00:00,null,null,373668,2019-04-01 00:00:00,Not yet recruiting
null,Phase 2a Clinical,C2A,GSK-3036656,70581,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,80,"An Early Bactericidal Activity, Safety and Tolerability of GSK-3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis",null,2021-07-16 12:00:00,2020-09-08 00:00:00,2020-09-08 00:00:00,343050,2019-03-27 00:00:00,Recruiting
null,Phase 2 Clinical,C2,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,220,Refining MDR-TB Treatment Regimens for Ultra Short Therapy,null,2021-08-20 12:00:00,2022-12-01 00:00:00,2022-12-01 00:00:00,372676,2019-05-01 00:00:00,Not yet recruiting
null,Phase 2a Clinical,C2A,linezolid,11036,"Safety,Efficacy,Bioequivalence,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,100,"Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM",null,2021-08-17 00:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,378146,2019-06-01 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,raltegravir,54488,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,460,Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis,null,2018-02-28 00:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,214156,2015-09-30 00:00:00,Recruiting
null,Phase 4 Clinical,C4,clarithromycin,2829,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 2 Clinical,C2,CC-11050,59386,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,200,TB Host Directed Therapy,null,2019-03-22 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,279898,2016-11-30 00:00:00,No longer recruiting
null,Phase 1 Clinical,C1,bortezomib,15954,Efficacy,Mycobacterium tuberculosis infection,221,N,null,Evaluating Whole Blood Bactericidal Activity of Bortezomib Against Mycobacterium Tuberculosis in Healthy Volunteers,null,null,null,null,263359,null,Status not specified
null,Phase 2a Clinical,C2A,SQ-109,31010,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,null,Evaluation of SQ-109 Plus PPI in Urea Breath Test-Positive Volunteers,2015-08-31 00:00:00,2014-03-31 00:00:00,null,2015-08-31 00:00:00,72716,2012-03-31 00:00:00,Terminated
null,Phase 2/Phase 3 Clinical,C23,trimethoprim + sulphamethoxazole,44363,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1354,Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV,2009-05-31 00:00:00,2006-06-20 12:00:00,null,2009-05-31 00:00:00,187839,2004-02-29 00:00:00,Terminated
null,Phase not specified,NS,albendazole,12132,Efficacy,Mycobacterium tuberculosis infection,221,N,140,Deworming Against Tuberculosis,2013-08-31 00:00:00,2011-06-23 00:00:00,null,2013-08-31 00:00:00,48176,2009-03-31 00:00:00,Completed
Asian Ancestry,Phase Not Applicable,PNA,moxifloxacin,12978,"Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,39,The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects,2013-01-31 00:00:00,2013-06-02 00:00:00,null,2013-01-31 00:00:00,139433,2011-11-30 00:00:00,Completed
null,Phase 3 Clinical,C3,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,416,"Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB",null,2006-09-03 12:00:00,null,null,150332,2004-05-14 00:00:00,Terminated
null,Phase 1b Clinical,C1B,VPM-1002,55569,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,24,Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison to BCG in Healthy Volunteers in South Africa,2011-03-31 00:00:00,2012-08-19 12:00:00,null,2011-03-31 00:00:00,65984,2010-04-30 00:00:00,Completed
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,121,Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis,null,2012-03-21 12:00:00,null,null,23035,2009-11-30 00:00:00,Terminated
null,Phase 2b Clinical,C2B,pretomanid,13323,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,240,"A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis",2018-02-07 00:00:00,2017-02-11 12:00:00,null,2018-02-07 00:00:00,210646,2014-10-23 00:00:00,Completed
null,Phase 2 Clinical,C2,efavirenz,10172,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,47,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam,2012-09-30 00:00:00,2012-10-19 12:00:00,null,2012-09-30 00:00:00,11188,2010-06-30 00:00:00,Completed
null,Phase 2 Clinical,C2,lopinavir + ritonavir,14681,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,40,Pharmacokinetics (PK) and Safety of Two Different Doses of Lopinavir/Ritonavir in HIV/Tuberculosis (TB) Co-Infected Patients Receiving Rifampicin Containing Anti-Tuberculosis Therapy,2015-12-31 00:00:00,2013-02-04 12:00:00,null,2015-12-31 00:00:00,67098,2010-11-30 00:00:00,Completed
null,Phase 1 Clinical,C1,sutezolid,11088,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,59,"Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers",2010-05-31 00:00:00,2012-02-20 12:00:00,null,2010-05-31 00:00:00,60906,2009-10-31 00:00:00,Completed
null,Phase 1 Clinical,C1,AERAS-402,53975,Safety,Mycobacterium tuberculosis infection,221,Y,54,A phase I study to test the safety of AERAS-402 in healthy infants previously vaccinated with the Bacille Calmette-Guerin (BCG) vaccine,null,2011-08-18 12:00:00,null,null,53622,2009-04-28 00:00:00,Status not specified
null,Phase 4 Clinical,C4,efavirenz,10172,Safety,Mycobacterium tuberculosis infection,221,N,156,Appropriate Timing of HAART in Co-infected HIV/TB Patients,2011-05-31 00:00:00,2012-03-31 00:00:00,2013-10-31 00:00:00,2011-05-31 00:00:00,61991,2009-10-31 00:00:00,Terminated
null,Phase 2 Clinical,C2,AERAS-402,53975,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,72,"A phase II, dose escalation study to determine the safety of AERAS-402 in adults who have had active tuberculosis",null,2011-02-06 12:00:00,null,null,59557,2008-10-17 00:00:00,Recruiting
null,Phase 1 Clinical,C1,"BCG vaccine, Organon",13624,Safety,Mycobacterium tuberculosis infection,221,Y,24,Study of AERAS-422 in Healthy Adults,2012-05-31 00:00:00,2013-04-21 12:00:00,null,2012-05-31 00:00:00,76756,2010-12-31 00:00:00,Completed
null,Phase 4 Clinical,C4,"rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals",69440,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,144,Clinical Trial for Comparing Safety and Efficacy of Bio-enhanced Rifampicin (Risorine) Capsule in newly diagnosed Pulmonary Tuberculosis in Adult Patients,null,2019-08-07 12:00:00,null,null,295037,2017-04-17 00:00:00,Not yet recruiting
null,Phase 4 Clinical,C4,raltegravir,54488,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,10,Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients,null,2013-01-05 12:00:00,null,null,63729,2010-10-31 00:00:00,Recruiting
null,Phase 2 Clinical,C2,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,2797,A Study of MVA-85A in Healthy Infants,2012-07-12 00:00:00,2011-11-20 12:00:00,null,2012-07-12 00:00:00,59405,2009-07-31 00:00:00,Completed
null,Phase 3 Clinical,C3,didanosine,2935,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,116,Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment,null,2008-11-28 00:00:00,2011-12-31 00:00:00,2011-12-31 00:00:00,10863,2006-06-30 00:00:00,Suspended
null,Phase 2 Clinical,C2,rifabutin,4229,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,15,Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz,2004-02-01 00:00:00,2002-02-04 12:00:00,2004-02-29 00:00:00,2004-02-01 00:00:00,10657,1999-11-30 00:00:00,Completed
null,Phase 2 Clinical,C2,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,37,Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-Positive Adults,2009-05-31 00:00:00,2010-10-20 12:00:00,null,2009-05-31 00:00:00,19230,2008-06-30 00:00:00,Completed
null,Phase 2 Clinical,C2,delamanid,16545,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,20,Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis,2011-05-12 00:00:00,2012-06-19 12:00:00,null,2011-05-12 00:00:00,66735,2010-02-28 00:00:00,Completed
null,Phase not specified,NS,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,59,"A multicenter, randomized controlled study to evaluate the clinical efficacy and safety of linezolid in patients with extensively drug resistant tuberculosis",null,null,null,null,173992,null,Status not specified
null,Phase 2 Clinical,C2,raltegravir,54488,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,140,EARNEST Rifabutin Pharmacokinetics (PK) Substudy,2014-01-31 00:00:00,2014-10-02 00:00:00,null,2014-01-31 00:00:00,90175,2012-05-03 00:00:00,Completed
null,Phase not specified,NS,lamivudine,3474,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,100,Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection,null,2014-11-07 12:00:00,null,null,126486,2012-09-01 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,posizolid,26493,"Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,Y,null,"A phase I, double-blind, placebo-controlled, flexible single day ascending dose (SDAD) study to evaluate safety, tolerability and pharmacokinetics (PK) of iv AZD-5847 in healthy subjects",null,2013-08-11 00:00:00,null,null,82840,2011-09-20 00:00:00,Status not specified
null,Phase 1 Clinical,C1,LL-3858,49162,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,null,A phase I study to evaluate the safety and pharmacokinetics of LL-3858,2007-10-07 00:00:00,2007-07-22 12:00:00,null,2007-10-07 00:00:00,8931,2005-04-01 00:00:00,Completed
null,Phase 3 Clinical,C3,moxifloxacin,12978,Efficacy,Mycobacterium tuberculosis infection,221,N,182,Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients,2012-10-31 00:00:00,2012-07-20 12:00:00,2012-02-29 00:00:00,2012-10-31 00:00:00,63801,2010-03-31 00:00:00,Terminated
null,Phase 2 Clinical,C2,ertapenem,12543,"Safety,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,12,PK/PD of Ertapenem in Patients with TB,2017-07-13 00:00:00,2019-05-18 12:00:00,null,2017-07-13 00:00:00,98848,2017-01-26 00:00:00,Completed
null,Phase 3 Clinical,C3,lopinavir + ritonavir,14681,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,30,Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso,null,2016-04-28 00:00:00,2014-11-27 00:00:00,2014-11-27 00:00:00,161441,2013-11-28 00:00:00,Not yet recruiting
null,Phase not specified,NS,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,100,Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection,null,2014-11-07 12:00:00,null,null,126486,2012-09-01 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,42,Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults,2016-04-30 00:00:00,2015-11-20 12:00:00,null,2016-04-30 00:00:00,120744,2013-07-31 00:00:00,Completed
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,105,Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z),2013-05-31 00:00:00,2015-02-20 12:00:00,null,2013-05-31 00:00:00,92275,2012-10-31 00:00:00,Completed
null,Phase 4 Clinical,C4,Rotarix,12813,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,28,A Study of the Interaction Between BCG And MenC Immunization,2018-06-27 00:00:00,2016-08-01 00:00:00,null,2018-06-27 00:00:00,162886,2014-06-20 00:00:00,Completed
null,Phase 3 Clinical,C3,lamivudine,3474,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,355,"Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis",2011-04-30 00:00:00,2008-08-19 12:00:00,null,2011-04-30 00:00:00,161275,2006-04-30 00:00:00,Completed
null,Phase 1 Clinical,C1,nelfinavir,8255,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,44,Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis,null,2002-05-02 12:00:00,null,null,10646,2000-02-25 00:00:00,Completed
null,Phase 4 Clinical,C4,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,200,RIFART,2011-04-19 00:00:00,2007-05-21 12:00:00,null,2011-04-19 00:00:00,131240,2005-03-15 00:00:00,Terminated
null,Phase 1 Clinical,C1,pretomanid,13323,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,16,Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects,2007-03-31 00:00:00,2009-07-20 12:00:00,null,2007-03-31 00:00:00,120522,2007-03-31 00:00:00,Completed
null,Phase 3 Clinical,C3,IMM-201,11115,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,347,A phase III study to evaluate the safety and efficacy of SRL-172 for the prevention of tuberculosis,1997-11-30 00:00:00,2000-03-21 12:00:00,null,1997-11-30 00:00:00,20002,1997-11-30 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,linezolid,11036,"Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,26,Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB),2010-05-31 00:00:00,2011-07-31 00:00:00,null,2010-05-31 00:00:00,48035,2009-04-30 00:00:00,Completed
null,Phase 1 Clinical,C1,lopinavir + ritonavir,14681,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,15,A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects,2008-10-01 00:00:00,2010-11-06 12:00:00,null,2008-10-01 00:00:00,25327,2008-08-31 00:00:00,Terminated
null,Phase 2 Clinical,C2,nevirapine,3700,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,42,Efficacy Safety Study Comparing two Doses of NVP After Initiating Rifampin-Containing TB Therapy,2009-12-31 00:00:00,2008-01-06 12:00:00,null,2009-12-31 00:00:00,10946,2005-10-31 00:00:00,Completed
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,207,"Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)",2013-07-31 00:00:00,2014-07-21 12:00:00,null,2013-07-31 00:00:00,83489,2012-03-31 00:00:00,Completed
null,Phase 1 Clinical,C1,lamivudine,3474,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,44,Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis,null,2002-05-02 12:00:00,null,null,10646,2000-02-25 00:00:00,Completed
null,Phase 1 Clinical,C1,delamanid,16545,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,13,Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis,2017-12-28 00:00:00,2015-10-04 12:00:00,null,2017-12-28 00:00:00,132087,2013-06-14 00:00:00,Completed
null,Phase 2 Clinical,C2,rifapentine,15102,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,60,"High-Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis",2010-05-31 00:00:00,2011-08-20 12:00:00,null,2010-05-31 00:00:00,63261,2009-04-30 00:00:00,Completed
null,Phase not specified,NS,indinavir,5321,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,18,"A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment",null,2014-03-24 12:00:00,null,null,100728,2012-01-17 00:00:00,Status not specified
null,Phase 1 Clinical,C1,zidovudine,44316,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,44,Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis,null,2002-05-02 12:00:00,null,null,10646,2000-02-25 00:00:00,Completed
null,Phase not specified,NS,levofloxacin,3492,Efficacy,Mycobacterium tuberculosis infection,221,N,30,A open-labeled study to assess the efficacy of levofloxacin in healthy volunteers,null,2014-05-03 12:00:00,null,null,113606,2012-09-30 00:00:00,Status not specified
null,Phase 4 Clinical,C4,lamivudine,3474,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,10,Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients,null,2013-01-05 12:00:00,null,null,63729,2010-10-31 00:00:00,Recruiting
null,Phase 3 Clinical,C3,Wei Ka,81037,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,10000,Phase III Clinical Study of Efficacy and Safety of Vaccae to Prevent Tuberculosis,2017-11-26 00:00:00,2016-02-20 12:00:00,null,2017-11-26 00:00:00,160177,2013-10-31 00:00:00,Completed
null,Phase 4 Clinical,C4,Prevnar 13,34281,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,28,A Study of the Interaction Between BCG And MenC Immunization,2018-06-27 00:00:00,2016-08-01 00:00:00,null,2018-06-27 00:00:00,162886,2014-06-20 00:00:00,Completed
null,Phase 2a Clinical,C2A,doxycycline hyclate,46927,Efficacy,Mycobacterium tuberculosis infection,221,N,200,Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana,2017-03-15 00:00:00,2017-01-22 12:00:00,null,2017-03-15 00:00:00,214864,2014-10-31 00:00:00,Completed
null,Phase 3 Clinical,C3,"tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences",49219,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1107,Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults,2015-01-31 00:00:00,2010-06-06 12:00:00,null,2015-01-31 00:00:00,195741,2008-03-31 00:00:00,Completed
null,Phase 4 Clinical,C4,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,150,Treatment of Latent Tuberculosis in Socially Marginalised Citizens,null,2020-02-16 12:00:00,2026-01-31 00:00:00,2026-01-31 00:00:00,310930,2017-10-27 00:00:00,Recruiting
null,Phase 1 Clinical,C1,AEC/BC02,81363,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,135,A Phase I Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried,null,2020-08-05 12:00:00,2019-08-31 00:00:00,2019-08-31 00:00:00,285854,2018-04-16 00:00:00,Recruiting
null,Phase not specified,NS,rifapentine,15102,Efficacy,Mycobacterium tuberculosis infection,221,N,92,"Randomized, Open-label, Comparative Study to Evaluate the Rifapentine in the Treatment of Patients Newly Diagnosed with Pulmonary Tuberculosis Negative and Smear-with Preserved Sensitivity of Mycobacteria",null,2014-01-16 12:00:00,2012-09-06 00:00:00,2012-09-06 00:00:00,168261,2011-09-27 00:00:00,Status not specified
null,Phase 4 Clinical,C4,Perchlozone,87251,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,200,"An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Perchlozone in the treatment of patients with pulmonary tuberculosis with MDR-TB, including HIV",null,2019-06-30 12:00:00,2017-12-31 00:00:00,2017-12-31 00:00:00,291547,2017-03-10 00:00:00,Status not specified
null,Phase 1 Clinical,C1,"ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis",68617,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,70,"Safety, Tolerability and Immunogenicity of the Vaccine Candidates ID-93 + AP10-602 and ID-93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects",2017-08-31 00:00:00,2018-02-10 12:00:00,null,2017-08-31 00:00:00,235751,2015-10-22 00:00:00,Completed
null,Phase 2 Clinical,C2,rifapentine,15102,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,153,Study of Daily Rifapentine for Pulmonary Tuberculosis,2014-09-30 00:00:00,2012-08-19 12:00:00,null,2014-09-30 00:00:00,39550,2010-04-30 00:00:00,Completed
null,Phase 1 Clinical,C1,levofloxacin,3492,"Bioequivalence,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,14,"Study to assess the bioequivalence of two oral formulations of levofloxacin tablets: FLEVOX (SERRAL, SA de CV), versus TAVANIC (Sanofi-Aventis of Mexico, SA de CV), after administration of a single dose- 500 mg to healthy adult subjects of both genders, in the fasting state",null,null,null,null,227604,null,No longer recruiting
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,262,NexGen EBA Radiological and Immunological Biomarkers of Sterilizing Drug Activity in Tuberculosis,2017-11-14 00:00:00,2017-06-16 12:00:00,null,2017-11-14 00:00:00,222933,2015-02-25 00:00:00,Completed
null,Phase 3 Clinical,C3,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,60,Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis,null,2018-09-19 12:00:00,2020-03-31 00:00:00,2020-03-31 00:00:00,242269,2016-05-30 00:00:00,Recruiting
null,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1556,Tuberculosis child multidrug-resistant preventive therapy,null,2018-04-22 12:00:00,2019-12-31 00:00:00,2019-12-31 00:00:00,259562,2016-01-01 00:00:00,No longer recruiting
null,Phase 2 Clinical,C2,moxifloxacin,12978,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,null,"A prospective, single-centre pharmacokinetic study to develop population pharmacokinetic models for second-line drugs in patients with multi-drug-resistant tuberculosis, evaluate the recommended dosage regimens and, if necessary, suggest new dosage regimens",null,null,null,null,304264,null,Status not specified
null,Phase 2a Clinical,C2A,"ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis",68617,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,107,Phase IIa Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers,null,2020-09-19 12:00:00,2020-06-30 00:00:00,2020-06-30 00:00:00,366580,2018-05-31 00:00:00,No longer recruiting
null,Phase 2 Clinical,C2,levofloxacin,3492,"Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,45,Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin,2014-09-30 00:00:00,2015-06-03 12:00:00,null,2014-09-30 00:00:00,254949,2013-10-31 00:00:00,Completed
null,Phase 4 Clinical,C4,moxifloxacin,12978,"Bioequivalence,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,32,"Open-label, randomized, crossover study of the comparative pharmacokinetics and bioequivalence of drugs moxifloxacin film-coated tablets 400 mg (JSC ""Synthesis"", Russia) and Avelox tablets, film-coated 400 mg (Bayer Pharma AG, Germany) in healthy volunteers on an empty stomach",null,2017-09-05 00:00:00,2017-10-16 00:00:00,2017-10-16 00:00:00,255583,2016-03-04 00:00:00,Status not specified
null,Phase 1 Clinical,C1,TBA-7371,107523,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,74,"A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371",2018-07-08 00:00:00,2019-12-19 12:00:00,null,2018-07-08 00:00:00,303756,2017-08-29 00:00:00,Completed
null,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB",null,2022-05-22 12:00:00,null,null,368916,2020-01-31 00:00:00,Terminated
null,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,3000,Novel Triple-Dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More,null,2022-01-19 12:00:00,2022-10-01 00:00:00,2022-10-01 00:00:00,372353,2019-09-30 00:00:00,Not yet recruiting
null,Phase not specified,NS,rifabutin,4229,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,150,Brief Bactericidal Activity of Anti-Tuberculosis Drugs,null,2018-03-21 12:00:00,2018-09-30 00:00:00,2018-09-30 00:00:00,210083,2015-11-30 00:00:00,Recruiting
null,Phase 3 Clinical,C3,pretomanid,13323,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,109,A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis,null,2017-06-30 00:00:00,2021-10-31 00:00:00,2021-10-31 00:00:00,219499,2015-03-31 00:00:00,No longer recruiting
Japanese Ancestry,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,6,An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB),2018-11-08 00:00:00,2017-05-20 00:00:00,null,2018-11-08 00:00:00,222400,2015-02-18 00:00:00,Completed
null,Phase 2 Clinical,C2,efavirenz,10172,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,155,Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis,2012-05-31 00:00:00,2011-12-30 00:00:00,null,2012-05-31 00:00:00,40948,2009-07-31 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,SQ-109,31010,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,140,"A phase IIb/III, international, multicenter, prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of chemotherapy regimens, including drug SQ-109 in patients with pulmonary multidrug-resistant mycobacterium tuberculosis",2016-09-30 00:00:00,2014-10-17 12:00:00,null,2016-09-30 00:00:00,168785,2012-06-27 00:00:00,Completed
null,Phase 2b Clinical,C2B,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,160,"Anti-bacterial Activity, Safety, and Tolerability of TMC-207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)",2012-10-31 00:00:00,2009-10-19 12:00:00,null,2012-10-31 00:00:00,9302,2007-06-30 00:00:00,Completed
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,32,A study to investigate the safety and efficacy of bedaquiline and linezolid chemotherapy for extensively drug-resistant pulmonary tuberculosis within 6 months period,null,null,null,null,280303,null,Status not specified
null,Phase 4 Clinical,C4,gatifloxacin,7017,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 2b Clinical,C2B,pravastatin,4155,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,30,Statin Adjunctive Therapy for TB: A Phase IIb Dose-finding Study of Pravastatin in Adults With Tuberculosis,null,2021-10-04 12:00:00,2020-06-16 00:00:00,2020-06-16 00:00:00,374083,2019-06-15 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,metformin hydrochloride,6050,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,150,Effect of metformin in treatment of non-diabetic pulmonary tuberculosis patients,null,2021-06-26 12:00:00,null,null,372893,2019-03-07 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,golotimod,25023,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,35,A Phase II Trial To Study SCV-07 in Tuberculosis (TB) Patients Receiving Standard Anti-TB Chemotherapy,null,2005-01-17 12:00:00,null,null,9345,2002-09-28 00:00:00,Status not specified
null,Phase 3 Clinical,C3,FS-1,104087,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,480,FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis,null,2016-04-21 12:00:00,2019-12-31 00:00:00,2019-12-31 00:00:00,246553,2013-12-31 00:00:00,Recruiting
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,2,MVA-85A Aerosol Versus Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M tb) Infection,2018-10-04 00:00:00,2018-01-19 12:00:00,null,2018-10-04 00:00:00,238674,2015-09-30 00:00:00,Terminated
null,Phase 2/Phase 3 Clinical,C23,moxifloxacin,12978,Efficacy,Mycobacterium tuberculosis infection,221,N,54,Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial,null,2021-10-20 12:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,379769,2019-07-01 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,32,A study to investigate the safety and efficacy of bedaquiline and linezolid chemotherapy for extensively drug-resistant pulmonary tuberculosis within 6 months period,null,null,null,null,280303,null,Status not specified
null,Phase 4 Clinical,C4,ofloxacin,52139,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 1 Clinical,C1,celecoxib,12135,"Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,18,Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers,2016-02-29 00:00:00,2018-03-21 12:00:00,null,2016-02-29 00:00:00,245694,2015-11-30 00:00:00,Completed
null,Phase 2a Clinical,C2A,TB/FLU-04L,98373,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,80,"A randomized, double-blind, placebo-controlled, phase II clinical trial of TB/FLU-04L TB vaccine in adult volunteers with signs of latent tuberculosis infection",null,2019-09-25 12:00:00,2018-05-30 00:00:00,2018-05-30 00:00:00,301908,2017-06-05 00:00:00,Status not specified
Asian Ancestry,Phase 1 Clinical,C1,pretomanid,13323,"Safety,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,62,Phase I clinical trial of single-dose of PA-824,null,2020-07-03 12:00:00,null,null,362102,2018-03-14 00:00:00,No longer recruiting
null,Phase 1 Clinical,C1,pretomanid,13323,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,48,Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function,null,2021-08-28 12:00:00,2020-10-01 00:00:00,2020-10-01 00:00:00,375406,2019-05-09 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,delamanid,16545,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,54,"Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis",2007-03-31 00:00:00,2009-03-21 12:00:00,null,2007-03-31 00:00:00,8842,2006-11-30 00:00:00,Completed
null,Phase 2 Clinical,C2,delamanid,16545,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,165,Study on Tuberculosis Resistant to Treatment,null,2021-05-23 12:00:00,null,null,369747,2019-02-01 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,"clofazimine (oral, tuberculosis), Novartis",91861,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,530,The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB,null,2018-08-20 12:00:00,2022-06-30 00:00:00,2022-06-30 00:00:00,228190,2016-04-30 00:00:00,Recruiting
Asian Ancestry,Phase 3 Clinical,C3,ranitidine,44309,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,400,Short Intensive Treatment For Children With Tuberculous Meningitis,null,2020-03-20 00:00:00,2022-08-01 00:00:00,2022-08-01 00:00:00,360104,2018-01-02 00:00:00,Not yet recruiting
null,Phase 2/Phase 3 Clinical,C23,"clofazimine (oral, tuberculosis), Novartis",91861,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,380,Clofazimine treatment of multidrug-resistant tuberculosis (MDRTB),2016-12-23 00:00:00,2018-06-21 12:00:00,null,2016-12-23 00:00:00,284370,2016-03-01 00:00:00,Terminated
null,Phase 2/Phase 3 Clinical,C23,VPM-1002,55569,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,2000,Phase II/III Study To Check The Efficacy And Safety Of Recombinant BCG Vaccine In TB Patients In India,null,2019-07-22 12:00:00,null,null,292836,2017-04-01 00:00:00,Not yet recruiting
null,Phase 2b Clinical,C2B,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,75,PanACEA Sutezolid Dose-finding and Combination Evaluation,null,2021-12-20 12:00:00,2020-02-29 00:00:00,2020-02-29 00:00:00,381674,2019-08-31 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,100,To observe if administration of drug namely linezolid along with standard four drug regimen in intensive(initial) phase of Tubercular meningitis will help reduce death and disability among patients when compared to standard four drug antitubercular drug therapy alone,null,2021-08-23 00:00:00,null,null,383209,2019-06-07 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,ESAT-6CFP10,95442,Efficacy,Mycobacterium tuberculosis infection,221,N,null,"Recombinant Mycobacterium tuberculosis allergen ESAT6-CFP10 for 18 to 65 years old healthy people: randomized, blinded, parallel-group phase III clinical trial",null,2018-06-08 12:00:00,2016-05-31 00:00:00,2016-05-31 00:00:00,252783,2016-02-17 00:00:00,Not yet recruiting
null,Phase 2a Clinical,C2A,"doxycycline (once-daily, oral controlled release), CollaGenex",48140,Efficacy,Mycobacterium tuberculosis infection,221,N,200,Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana,2017-03-15 00:00:00,2017-01-22 12:00:00,null,2017-03-15 00:00:00,214864,2014-10-31 00:00:00,Completed
null,Phase 2 Clinical,C2,raltegravir,54488,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,155,Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis,2012-05-31 00:00:00,2011-12-30 00:00:00,null,2012-05-31 00:00:00,40948,2009-07-31 00:00:00,Completed
null,Phase 3 Clinical,C3,ESAT-6CFP10,95442,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,96,Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen for Children,2018-03-31 00:00:00,2019-02-20 12:00:00,null,2018-03-31 00:00:00,285889,2016-10-31 00:00:00,Completed
null,Phase 1b Clinical,C1B,H4:IC31,48499,"Safety,Efficacy,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,84,"Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents",2016-12-09 00:00:00,2017-09-19 12:00:00,null,2016-12-09 00:00:00,223463,2015-05-31 00:00:00,Completed
null,Phase 1 Clinical,C1,dolutegravir,59062,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,16,A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers,null,2020-03-31 00:00:00,2018-03-31 00:00:00,2018-03-31 00:00:00,303292,2017-10-31 00:00:00,Not yet recruiting
null,Phase 0 Clinical,C0,emtricitabine,4728,Efficacy,Mycobacterium tuberculosis infection,221,N,419,TasP in Correctional Facilities,2018-03-31 00:00:00,2018-04-08 12:00:00,null,2018-03-31 00:00:00,280225,2016-02-01 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,dolutegravir,59062,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,60,"Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients",null,2020-03-25 12:00:00,2018-11-03 00:00:00,2018-11-03 00:00:00,329251,2018-01-18 00:00:00,Recruiting
null,Phase 1 Clinical,C1,doravirine,74480,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,11,"Doravirine, Rifapentine and Isoniazid Interaction",null,2021-07-05 12:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,374387,2019-04-30 00:00:00,Recruiting
null,Phase 2 Clinical,C2,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,302,Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants,2012-03-31 00:00:00,2012-11-19 12:00:00,null,2012-03-31 00:00:00,65639,2010-07-31 00:00:00,Completed
null,Phase 2a Clinical,C2A,"ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis",68617,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,60,Phase IIa ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion,2017-01-31 00:00:00,2017-10-19 12:00:00,null,2017-01-31 00:00:00,231367,2015-06-30 00:00:00,Completed
null,Phase 4 Clinical,C4,"lamivudine + abacavir + zidovudine, GSK",26574,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,70,Tuberculosis and HIV Immune Reconstitution Syndrome Trial (THIRST),2007-09-30 00:00:00,2006-09-05 12:00:00,2007-09-30 00:00:00,2007-09-30 00:00:00,47398,2004-06-30 00:00:00,Completed
null,Phase 1 Clinical,C1,rifabutin,4229,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,33,TMC-207 +/- Rifabutin/Rifampin,2012-05-23 00:00:00,2014-02-09 12:00:00,null,2012-05-23 00:00:00,76765,2011-10-21 00:00:00,Completed
African Ancestry,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,24,"A phase I study of a new tuberculosis (TB) vaccine, MVA-85A, in healthy volunteers with HIV",2011-01-31 00:00:00,2010-12-21 12:00:00,null,2011-01-31 00:00:00,23059,2008-08-31 00:00:00,Completed
null,Phase 2 Clinical,C2,doxycycline hyclate,46927,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,40,Doxycycline in Human Pulmonary Tuberculosis,2017-06-30 00:00:00,2018-01-19 12:00:00,null,2017-06-30 00:00:00,261320,2015-09-30 00:00:00,Completed
null,Phase 3 Clinical,C3,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,145,Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin,2010-12-31 00:00:00,2009-04-07 12:00:00,null,2010-12-31 00:00:00,10947,2007-01-31 00:00:00,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,12,A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers,2005-08-31 00:00:00,2005-07-20 12:00:00,2005-07-31 00:00:00,2005-08-31 00:00:00,10872,2003-03-31 00:00:00,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,16,"A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG",2006-06-30 00:00:00,2005-09-19 12:00:00,2005-01-31 00:00:00,2006-06-30 00:00:00,10874,2003-05-31 00:00:00,Completed
null,Phase 2 Clinical,C2,rifapentine,15102,Bioavailability,Mycobacterium tuberculosis infection,221,Y,null,A phase II trial of rifapentine in comparision with rifampicin to evaluate bioavailability in treatment of patients with pulmonary tuberculosis,null,1990-04-21 12:00:00,null,null,15342,1987-12-31 00:00:00,Status not specified
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,233,"To Evaluate the Safety, Tolerability, and Efficacy of TMC-207 as Part of an Individualized Multi-Drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-Positive Pulmonary MDR-TB",2013-01-31 00:00:00,2012-01-20 12:00:00,null,2013-01-31 00:00:00,56974,2009-09-30 00:00:00,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,12,TCell Turnover Following Vaccination With MVA-85A,2010-01-31 00:00:00,2010-02-19 12:00:00,null,2010-01-31 00:00:00,11182,2007-10-31 00:00:00,Completed
null,Phase 2 Clinical,C2,rifabutin,4229,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,47,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam,2012-09-30 00:00:00,2012-10-19 12:00:00,null,2012-09-30 00:00:00,11188,2010-06-30 00:00:00,Completed
null,Phase not specified,NS,nevirapine,3700,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,100,Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection,null,2014-11-07 12:00:00,null,null,126486,2012-09-01 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,AERAS-402,53975,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,487,Study of AERAS-402 in Healthy Infants,2014-04-30 00:00:00,2013-01-19 12:00:00,null,2014-04-30 00:00:00,70158,2010-09-30 00:00:00,Completed
null,Phase not specified,NS,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,150,Brief Bactericidal Activity of Anti-Tuberculosis Drugs,null,2018-03-21 12:00:00,2018-09-30 00:00:00,2018-09-30 00:00:00,210083,2015-11-30 00:00:00,Recruiting
African Ancestry,Phase 2 Clinical,C2,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,650,"Efficacy Against TB Disease, Safety, and Immunogenicity of MVA-85A/AERAS-485 in HIV-Infected Adults",2014-09-30 00:00:00,2013-11-19 12:00:00,null,2014-09-30 00:00:00,67841,2011-07-31 00:00:00,Completed
null,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,650,The Treatment of Tuberculosis in HIV-Infected Patients,1997-07-31 00:00:00,null,null,1997-07-31 00:00:00,10643,null,Completed
null,Phase not specified,NS,nevirapine,3700,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,53,Population Pharmacokinetics of Nevirapine in Combination With Rifampicin-Based Short Course Chemotherapy in HIV- and Tuberculosis-Infected South African Patients,null,null,null,null,149504,null,Completed
null,Phase 1 Clinical,C1,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,33,TMC-207 +/- Rifabutin/Rifampin,2012-05-23 00:00:00,2014-02-09 12:00:00,null,2012-05-23 00:00:00,76765,2011-10-21 00:00:00,Completed
null,Phase 1 Clinical,C1,"golotimod (oral), SciClone/Verta",55521,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,24,Phase I Trial to Compare Oral Formulation of Golotimod Versus that of Subcutaneous and Sublingual Formulations of Golotimod in Healthy Volunteers for the treatment of Tuberculosis (TB),null,2008-09-13 12:00:00,2006-12-31 00:00:00,2006-12-31 00:00:00,8932,2006-05-25 00:00:00,Status not specified
null,Phase 3 Clinical,C3,delamanid,16545,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,511,Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug Resistant Tuberculosis,2016-07-04 00:00:00,2013-12-22 12:00:00,null,2016-07-04 00:00:00,80386,2011-09-02 00:00:00,Completed
null,Phase not specified,NS,losartan,3517,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,13,The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity,2011-06-30 00:00:00,2012-10-20 12:00:00,null,2011-06-30 00:00:00,122291,2010-07-01 00:00:00,Completed
null,Phase 1 Clinical,C1,SSI H56-IC31,74849,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,25,Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis,2013-06-30 00:00:00,2014-03-21 12:00:00,null,2013-06-30 00:00:00,158535,2011-11-30 00:00:00,Completed
null,Phase 3 Clinical,C3,lamivudine,3474,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,540,Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis,2010-05-31 00:00:00,2008-04-07 12:00:00,null,2010-05-31 00:00:00,145651,2006-01-31 00:00:00,Completed
Asian Ancestry,Phase 2 Clinical,C2,linezolid,11036,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,64,"A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK",null,2019-04-01 12:00:00,2018-12-31 00:00:00,2018-12-31 00:00:00,265899,2016-12-10 00:00:00,Recruiting
null,Phase 2/Phase 3 Clinical,C23,nevirapine,3700,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,570,Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients,2011-04-30 00:00:00,2010-03-07 12:00:00,2011-03-31 00:00:00,2011-04-30 00:00:00,10948,2007-12-31 00:00:00,Completed
null,Phase not specified,NS,IMM-201,11115,Efficacy,Mycobacterium tuberculosis infection,221,N,337,"A dose-finding, multicenter, open-label study to investigate the efficacy of SRL-172 vaccine in the treatment of multidrug-resistant pulmonary tuberculosis",null,2003-05-01 12:00:00,null,null,110339,2001-01-09 00:00:00,Status not specified
null,Phase 3 Clinical,C3,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,135,Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB,2013-02-28 00:00:00,2009-09-04 12:00:00,null,2013-02-28 00:00:00,114300,2007-06-30 00:00:00,Completed
null,Phase 3 Clinical,C3,linezolid,11036,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,109,A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis,null,2017-06-30 00:00:00,2021-10-31 00:00:00,2021-10-31 00:00:00,219499,2015-03-31 00:00:00,No longer recruiting
null,Phase 4 Clinical,C4,Priorix,11457,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,28,A Study of the Interaction Between BCG And MenC Immunization,2018-06-27 00:00:00,2016-08-01 00:00:00,null,2018-06-27 00:00:00,162886,2014-06-20 00:00:00,Completed
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,65,Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With,2011-08-31 00:00:00,2013-02-19 12:00:00,null,2011-08-31 00:00:00,71107,2010-10-31 00:00:00,Completed
null,Phase not specified,NS,rifabutin,4229,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,215,Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen,2004-06-30 00:00:00,2001-05-05 12:00:00,2003-02-28 00:00:00,2004-06-30 00:00:00,10653,1999-02-28 00:00:00,Completed
null,Phase not specified,NS,"thalidomide, Celgene",8050,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,15,Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role,2000-08-01 00:00:00,null,null,2000-08-01 00:00:00,150307,null,Completed
null,Phase 3 Clinical,C3,zidovudine,44316,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,355,"Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis",2011-04-30 00:00:00,2008-08-19 12:00:00,null,2011-04-30 00:00:00,161275,2006-04-30 00:00:00,Completed
null,Phase 4 Clinical,C4,lopinavir + ritonavir,14681,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,30,An Evaluation of the Pharmacological Interaction of Lopinavir/ritonavir and Rifampin,2012-12-31 00:00:00,2011-02-05 12:00:00,null,2012-12-31 00:00:00,171009,2008-11-30 00:00:00,Completed
null,Phase 4 Clinical,C4,"rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals",69440,Efficacy,Mycobacterium tuberculosis infection,221,N,60,Combination of Two Drugs in Tuberculosis Treatment,null,null,null,null,224091,null,Recruiting
null,Phase 4 Clinical,C4,rifabutin,4229,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,10,Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients,null,2013-01-05 12:00:00,null,null,63729,2010-10-31 00:00:00,Recruiting
null,Phase 0 Clinical,C0,"BCG vaccine, Organon",13624,Efficacy,Mycobacterium tuberculosis infection,221,N,10,Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naive Healthy Adults in the US,2015-10-13 00:00:00,2017-09-28 00:00:00,null,2015-10-13 00:00:00,227341,2015-05-31 00:00:00,Completed
null,Phase 1 Clinical,C1,ESAT-6CFP10,95442,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,24,Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10,2013-12-31 00:00:00,2016-01-20 12:00:00,null,2013-12-31 00:00:00,163196,2013-09-30 00:00:00,Completed
null,Phase not specified,NS,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,39,"An open-label, comparative, multicenter trial to evaluate long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis",null,2005-06-19 12:00:00,null,null,113726,2003-02-28 00:00:00,Status not specified
null,Phase not specified,NS,aldesleukin,6306,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,110,"A randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of IL-2 for the treatment of patients with pulmonary tuberculosis",null,2005-03-12 12:00:00,null,null,73321,2002-11-21 00:00:00,Status not specified
null,Phase 3 Clinical,C3,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1107,Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults,2015-01-31 00:00:00,2010-06-06 12:00:00,null,2015-01-31 00:00:00,195741,2008-03-31 00:00:00,Completed
null,Phase 3 Clinical,C3,lamivudine,3474,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,116,Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment,null,2008-11-28 00:00:00,2011-12-31 00:00:00,2011-12-31 00:00:00,10863,2006-06-30 00:00:00,Suspended
null,Phase 2 Clinical,C2,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,181,Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) in Healthy Adults,2009-04-30 00:00:00,2010-08-20 12:00:00,null,2009-04-30 00:00:00,11263,2008-04-30 00:00:00,Completed
null,Phase 2 Clinical,C2,Recombivax HB,6748,Efficacy,Mycobacterium tuberculosis infection,221,N,185,A Trial Investigating the Influence of BCG and Hepatitis B Immunization at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study,2016-06-30 00:00:00,2017-08-30 00:00:00,null,2016-06-30 00:00:00,229498,2015-03-31 00:00:00,Completed
null,Phase 4 Clinical,C4,rifapentine,15102,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,null,Pharmacokinetics of rifapentine and isoniazid and NAT2 and SLCO1B1 polymorphisms in pediatric Thai patients with latent tuberculosis infection,null,2021-09-20 12:00:00,2020-06-30 00:00:00,2020-06-30 00:00:00,379095,2019-06-01 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,566,Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention,null,2017-07-28 00:00:00,2018-12-31 00:00:00,2018-12-31 00:00:00,228560,2015-03-31 00:00:00,Recruiting
null,Phase 3 Clinical,C3,"lamivudine + zidovudine, GlaxoSmithKline",16696,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,135,Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB,2013-02-28 00:00:00,2009-09-04 12:00:00,null,2013-02-28 00:00:00,114300,2007-06-30 00:00:00,Completed
Asian Ancestry,Phase 1 Clinical,C1,"rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer",89460,"Safety,Bioequivalence,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,21,"Bioequivalence Study Comparing Rifampicin In A Fixed-dose Combination (Rifampicin + Isoniazid, Myrin 2) And The Reference Drug (Rifampicin, Rimactane)",2011-05-31 00:00:00,2013-08-19 12:00:00,null,2011-05-31 00:00:00,164313,2011-04-30 00:00:00,Completed
null,Phase 1 Clinical,C1,"tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences",49219,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,26,Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid,null,2019-03-22 00:00:00,2018-02-28 00:00:00,2018-02-28 00:00:00,265766,2016-10-21 00:00:00,Recruiting
null,Phase 1/Phase 2 Clinical,C12,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,72,EMaBS TB Vaccine Study,null,2021-03-22 12:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,354327,2018-12-01 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,2500,Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals,null,2021-07-20 12:00:00,2023-03-31 00:00:00,2023-03-31 00:00:00,364544,2019-03-31 00:00:00,Not yet recruiting
null,Phase 2b Clinical,C2B,macozinone,90085,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,192,"International, multicenter, double-blind, placebo-controlled, randomized trial to evaluate the efficacy, safety and pharmacokinetics of PBTZ-169 when used in combination therapy in patients with tuberculosis of respiratory organs with bacterial excretion and drug resistance",null,2019-12-07 12:00:00,2020-03-01 00:00:00,2020-03-01 00:00:00,316145,2017-08-17 00:00:00,Status not specified
Asian Ancestry,Phase 2 Clinical,C2,stavudine,4481,"Safety,Efficacy,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,35,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa,2010-10-31 00:00:00,2011-05-06 12:00:00,null,2010-10-31 00:00:00,11187,2009-02-28 00:00:00,Completed
null,Phase 2 Clinical,C2,rifabutin,4229,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,40,Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw,null,2017-09-04 12:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,226826,2015-06-30 00:00:00,Recruiting
null,Phase not specified,NS,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,592,Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings,null,2011-11-06 12:00:00,null,null,8820,2009-08-31 00:00:00,Completed
null,Phase 4 Clinical,C4,imipenem + cilastatin,44406,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,69,A study to evaluate the efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in patients with newly diagnosed pulmonary tuberculosis,null,null,null,null,280029,null,Status not specified
null,Phase 3 Clinical,C3,delamanid,16545,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,750,Evaluating Newly Approved Drugs for Multidrug-resistant TB,null,2019-04-02 00:00:00,2021-04-30 00:00:00,2021-04-30 00:00:00,259506,2016-12-31 00:00:00,Recruiting
null,Phase 4 Clinical,C4,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,140,"Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis",null,2012-03-22 12:00:00,2010-12-31 00:00:00,2010-12-31 00:00:00,328802,2009-12-01 00:00:00,No longer recruiting
null,Phase 1 Clinical,C1,pretomanid,13323,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,36,"Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects",null,2020-04-01 12:00:00,2019-12-11 00:00:00,2019-12-11 00:00:00,227410,2017-12-11 00:00:00,Recruiting
null,Phase 1 Clinical,C1,levofloxacin,3492,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,24,A study to evaluate the pharmacokinetics of levofloxacin in children who received levofloxacin-based tuberculosis preventive therapy,null,null,null,null,380303,null,Status not specified
null,Phase 2 Clinical,C2,tenofovir disoproxil fumarate,14493,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,230,Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis,null,2020-08-28 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,334027,2018-04-15 00:00:00,Recruiting
null,Phase 4 Clinical,C4,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 4 Clinical,C4,meropenem,3616,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 2 Clinical,C2,bedaquiline,51310,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,36,"A study on the uptake, distribution and excretion of bedaquiline, a medicine against tuberculosis, in people with type 2 diabetes",null,2019-12-31 00:00:00,2018-12-31 00:00:00,2018-12-31 00:00:00,331962,2018-06-01 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,delamanid,16545,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,500,Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance,null,2021-09-29 00:00:00,2022-12-31 00:00:00,2022-12-31 00:00:00,375499,2019-06-30 00:00:00,Not yet recruiting
null,Phase 2b Clinical,C2B,ESAT-6CFP10,95442,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,1044,Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65,2015-09-30 00:00:00,2017-07-20 12:00:00,null,2015-09-30 00:00:00,224675,2015-03-31 00:00:00,Completed
null,Phase 1 Clinical,C1,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,50,Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-Negative Adults,2005-05-31 00:00:00,2006-11-20 12:00:00,null,2005-05-31 00:00:00,9540,2004-07-31 00:00:00,Completed
Japanese Ancestry,Phase 3 Clinical,C3,ranitidine,44309,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,400,Short Intensive Treatment For Children With Tuberculous Meningitis,null,2020-03-20 00:00:00,2022-08-01 00:00:00,2022-08-01 00:00:00,360104,2018-01-02 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,ivermectin,3412,Efficacy,Mycobacterium tuberculosis infection,221,N,120,Tuberculosis - Learning the Impact of Nutrition,null,2021-07-25 00:00:00,2023-12-31 00:00:00,2023-12-31 00:00:00,347635,2019-06-30 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,linezolid,11036,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,36,Pharmacokinetic Study of Linezolid for TB Meningitis,null,2021-09-15 00:00:00,2020-06-30 00:00:00,2020-06-30 00:00:00,340851,2019-06-30 00:00:00,Not yet recruiting
null,Phase 2/Phase 3 Clinical,C23,linezolid,11036,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,900,A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis,null,2020-07-10 12:00:00,2022-03-12 00:00:00,2022-03-12 00:00:00,333435,2018-03-21 00:00:00,Recruiting
null,Phase 3 Clinical,C3,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,500,The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB,null,2021-06-27 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,369109,2019-03-08 00:00:00,Recruiting
null,Phase 2 Clinical,C2,DAR-901,90231,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,650,DAR-901 TB Booster Vaccine to Prevent TB in Adolescents,null,2018-07-21 12:00:00,2019-12-31 00:00:00,2019-12-31 00:00:00,256110,2016-03-31 00:00:00,No longer recruiting
null,Phase 3 Clinical,C3,simvastatin,44313,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,321,"Simvastatin and sputum conversion in pulmonary tuberculosis: a double-blinded, randomized, controlled trial",null,2020-07-21 12:00:00,null,null,330023,2018-04-01 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,cadi-05,55173,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,300,Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients,2012-03-31 00:00:00,2009-07-20 12:00:00,null,2012-03-31 00:00:00,10866,2007-03-31 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,"once-daily naproxen (oral controlled release, pain), Alvogen",12013,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial,null,2016-04-07 12:00:00,null,null,199754,2014-01-31 00:00:00,Terminated
null,Phase 1 Clinical,C1,midazolam hydrochloride,44303,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,37,"Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers",2011-03-31 00:00:00,2012-08-19 12:00:00,null,2011-03-31 00:00:00,68204,2010-04-30 00:00:00,Completed
null,Phase 3 Clinical,C3,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,3000,Brief Rifapentine-Isoniazid Evaluation for TB Prevention,2017-11-14 00:00:00,2014-09-12 12:00:00,null,2017-11-14 00:00:00,79741,2012-05-23 00:00:00,Completed
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy,Bioequivalence,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,410,"Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment TBTC/UITB Study 28",null,2008-08-20 12:00:00,null,null,155451,2006-05-01 00:00:00,Recruiting
null,Phase 2 Clinical,C2,lamivudine,3474,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,155,Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis,2012-05-31 00:00:00,2011-12-30 00:00:00,null,2012-05-31 00:00:00,40948,2009-07-31 00:00:00,Completed
null,Phase not specified,NS,ritonavir,7310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,18,"A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment",null,2014-03-24 12:00:00,null,null,100728,2012-01-17 00:00:00,Status not specified
Asian Ancestry,Phase 2 Clinical,C2,efavirenz,10172,"Safety,Efficacy,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,35,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa,2010-10-31 00:00:00,2011-05-06 12:00:00,null,2010-10-31 00:00:00,11187,2009-02-28 00:00:00,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,12,Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB,2007-04-30 00:00:00,2007-12-21 12:00:00,null,2007-04-30 00:00:00,10941,2005-08-31 00:00:00,Completed
null,Phase 1 Clinical,C1,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,19,Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis,2017-12-29 00:00:00,2011-04-20 12:00:00,null,2017-12-29 00:00:00,192117,2008-12-29 00:00:00,Completed
null,Phase 2 Clinical,C2,VP-101,12014,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,288,Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB),2014-12-31 00:00:00,2013-04-21 12:00:00,null,2014-12-31 00:00:00,142323,2010-12-31 00:00:00,Completed
null,Phase 4 Clinical,C4,tenofovir disoproxil fumarate,14493,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,780,Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis,2010-07-31 00:00:00,2008-11-05 12:00:00,null,2010-07-31 00:00:00,10681,2006-08-31 00:00:00,Completed
null,Phase not specified,NS,linezolid,11036,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,19,Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis,null,null,null,null,150522,null,Completed
null,Phase 1/Phase 2 Clinical,C12,gatifloxacin,7017,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,70,"Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis",2007-12-31 00:00:00,2006-06-20 12:00:00,null,2007-12-31 00:00:00,10869,2004-02-29 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,58,Improving Retreatment Success,2017-07-17 00:00:00,2016-03-21 12:00:00,null,2017-07-17 00:00:00,182040,2013-11-30 00:00:00,Completed
null,Phase 4 Clinical,C4,lopinavir + ritonavir,14681,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,9,Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin,2018-12-31 00:00:00,2018-05-30 00:00:00,null,2018-12-31 00:00:00,93494,2016-02-29 00:00:00,Terminated
null,Phase 1 Clinical,C1,raltegravir,54488,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,18,The Effect of Intermittent Rifampicin on Raltegravir,2013-07-31 00:00:00,2014-04-07 12:00:00,null,2013-07-31 00:00:00,80394,2012-01-31 00:00:00,Completed
null,Phase 1 Clinical,C1,AERAS-407 rBCG,62397,Safety,Mycobacterium tuberculosis infection,221,Y,24,Study of AERAS-422 in Healthy Adults,2012-05-31 00:00:00,2013-04-21 12:00:00,null,2012-05-31 00:00:00,76756,2010-12-31 00:00:00,Completed
null,Phase not specified,NS,midazolam hydrochloride,44303,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,13,The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity,2011-06-30 00:00:00,2012-10-20 12:00:00,null,2011-06-30 00:00:00,122291,2010-07-01 00:00:00,Completed
null,Phase 2 Clinical,C2,lopinavir + ritonavir,14681,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,140,EARNEST Rifabutin Pharmacokinetics (PK) Substudy,2014-01-31 00:00:00,2014-10-02 00:00:00,null,2014-01-31 00:00:00,90175,2012-05-03 00:00:00,Completed
null,Phase 2a Clinical,C2A,posizolid,26493,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,75,Phase IIa EBA Trial of AZD-5847,2013-12-24 00:00:00,2015-03-27 12:00:00,null,2013-12-24 00:00:00,84246,2012-12-05 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,raltegravir,54488,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,108,"Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-containing Antiretroviral Therapy (ART) Regimen in Infants and Children Infected With HIV and TB",null,2016-10-29 00:00:00,2020-04-30 00:00:00,2020-04-30 00:00:00,102102,2014-05-31 00:00:00,Recruiting
null,Phase 3 Clinical,C3,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1931,Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis,2014-02-28 00:00:00,2010-04-22 12:00:00,null,2014-02-28 00:00:00,49258,2008-01-01 00:00:00,Completed
null,Phase 1 Clinical,C1,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,15,Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine,2008-08-24 00:00:00,2009-10-19 12:00:00,null,2008-08-24 00:00:00,10943,2007-06-30 00:00:00,Terminated
null,Phase 3 Clinical,C3,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,null,A Study to Evaluate the Efficacy and Safety of TMC-207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis,null,2016-07-20 12:00:00,null,null,87533,2014-03-31 00:00:00,Terminated
null,Phase not specified,NS,zidovudine,44316,"Safety,Efficacy,Bioavailability",Mycobacterium tuberculosis infection,221,N,120,"Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression",null,2008-08-03 12:00:00,null,null,136052,2006-05-29 00:00:00,Completed
null,Phase 2 Clinical,C2,pretomanid,13323,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,207,"Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)",2013-07-31 00:00:00,2014-07-21 12:00:00,null,2013-07-31 00:00:00,83489,2012-03-31 00:00:00,Completed
null,Phase 2 Clinical,C2,SQ-109,31010,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,365,"Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design",2015-03-31 00:00:00,2015-08-20 12:00:00,null,2015-03-31 00:00:00,109063,2013-04-30 00:00:00,Completed
null,Phase 4 Clinical,C4,emtricitabine,4728,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,780,Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis,2010-07-31 00:00:00,2008-11-05 12:00:00,null,2010-07-31 00:00:00,10681,2006-08-31 00:00:00,Completed
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,40,Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A,2014-08-31 00:00:00,2015-01-20 12:00:00,null,2014-08-31 00:00:00,91280,2012-09-30 00:00:00,Completed
null,Phase 4 Clinical,C4,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,817,"A randomized, double-blind, placebo-controlled trial to investigate the effect of intensified treatment with high dose rifampicin and levofloxacin for adult patients with tuberculous meningitis",2015-03-15 00:00:00,2013-08-07 12:00:00,null,2015-03-15 00:00:00,75317,2011-04-18 00:00:00,Completed
null,Phase 1 Clinical,C1,"BCG vaccine, Organon",13624,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,120,Challenge Model for Assessment of Human TB Immunity,null,2016-10-19 12:00:00,2016-06-30 00:00:00,2016-06-30 00:00:00,149358,2014-06-30 00:00:00,Completed
null,Phase 4 Clinical,C4,rifabutin,4229,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,20,Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB,2005-06-30 00:00:00,2002-05-06 12:00:00,2002-02-28 00:00:00,2005-06-30 00:00:00,10656,2000-02-29 00:00:00,Completed
null,Phase not specified,NS,Glutoxim,28379,Efficacy,Mycobacterium tuberculosis infection,221,N,54,Glutoxim in the Surgical Treatment of Patients With Pulmonary Tuberculosis,2007-01-01 00:00:00,null,null,2007-01-01 00:00:00,149224,null,Completed
null,Phase not specified,NS,efavirenz,10172,"Safety,Efficacy,Bioavailability",Mycobacterium tuberculosis infection,221,N,120,"Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression",null,2008-08-03 12:00:00,null,null,136052,2006-05-29 00:00:00,Completed
null,Phase 3 Clinical,C3,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,7731,A 3 Months of Weekly Rifapentine and Isoniazid for M Tuberculosis Infection,2013-09-30 00:00:00,2003-10-20 12:00:00,null,2013-09-30 00:00:00,10659,2001-06-30 00:00:00,Completed
null,Phase 1 Clinical,C1,lopinavir + ritonavir,14681,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,16,TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer,2009-05-31 00:00:00,2011-05-06 12:00:00,null,2009-05-31 00:00:00,42128,2009-02-28 00:00:00,Completed
null,Phase 1 Clinical,C1,simeprevir,39069,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,21,"TMC-435350-TiDP16-C105:  Phase I, Three-Way Crossover, Drug-Drug Interaction Between TMC-435350 and Rifampin After Multiple Dosing",2008-12-31 00:00:00,2010-06-30 00:00:00,null,2008-12-31 00:00:00,25800,2008-06-30 00:00:00,Completed
null,Phase 2 Clinical,C2,H4:IC31,48499,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,990,"A Randomized, Placebo-Controlled, Partially-Blinded, Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents",2017-10-06 00:00:00,2016-06-19 12:00:00,null,2017-10-06 00:00:00,176219,2014-02-28 00:00:00,Completed
Asian Ancestry,Phase 2 Clinical,C2,nevirapine,3700,"Safety,Efficacy,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,35,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa,2010-10-31 00:00:00,2011-05-06 12:00:00,null,2010-10-31 00:00:00,11187,2009-02-28 00:00:00,Completed
null,Phase 3 Clinical,C3,meloxicam,3610,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,200,TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial,null,2016-08-19 12:00:00,2015-03-01 00:00:00,2015-03-01 00:00:00,172626,2014-04-30 00:00:00,Recruiting
null,Phase not specified,NS,Perchlozone,87251,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,340,"Multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of the drug Perhlozone in the treatment of patients with pulmonary MDR MBT, including the presence of HIV infection",null,2016-07-28 12:00:00,2016-05-03 00:00:00,2016-05-03 00:00:00,183939,2014-04-08 00:00:00,Status not specified
null,Phase 3 Clinical,C3,picroliv,9354,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,260,Evaluation of Hepatoprotective Effect of Picroliv in Patients Receiving Multi Drug Therapy of Tuberculosis,2010-05-01 00:00:00,2007-06-21 12:00:00,null,2010-05-01 00:00:00,127798,2005-03-01 00:00:00,Completed
null,Phase not specified,NS,rifapentine,15102,Safety,Mycobacterium tuberculosis infection,221,N,17,"A Non-randomized, Uncontrolled, Single-group Study of Short-course Isoniazid plus Rifapentine Directly Observed Therapy for Latent Tuberculosis in Solid-organ Transplant Candidates",null,null,null,null,159244,null,Completed
null,Phase 3 Clinical,C3,isoniazid + rifampicin + pyrazinamide + ethambutol,98013,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,300,"Using electronic monitors and a smartphone app to improve treatment adherence of new pulmonary tuberculosis patients in Tibet, China",null,2020-12-21 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,359917,2018-09-01 00:00:00,Recruiting
null,Phase 1 Clinical,C1,GamTBvac,107803,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,60,Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine 'GamTBvac' Against the Tuberculosis,2017-12-13 00:00:00,2019-05-07 12:00:00,null,2017-12-13 00:00:00,309614,2017-01-15 00:00:00,Completed
null,Phase Not Applicable,PNA,tedizolid phosphate,30819,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,null,Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single-Doses of Tedizolid Plus Rifampicin in Healthy Volunteers,null,null,null,null,331225,null,Status not specified
null,Phase 2/Phase 3 Clinical,C23,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,2927,The Correlate of Risk Targeted Intervention Study,null,2019-01-10 12:00:00,2019-12-31 00:00:00,2019-12-31 00:00:00,258043,2016-09-20 00:00:00,No longer recruiting
null,Phase 3 Clinical,C3,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,4027,Evaluation of the Effect of 3HP versus Periodic 3HP versus 6H in HIV-Positive Individuals,null,2019-03-22 12:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,281055,2016-11-30 00:00:00,No longer recruiting
null,Phase 2b Clinical,C2B,delpazolid,76307,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,null,A clinical trial of RMX-2001 in multidrug-resistant tuberculosis (MDR-TB) in USA,null,null,null,null,370698,null,Planned
null,Phase 4 Clinical,C4,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,500,"Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings",null,2019-10-27 12:00:00,2021-04-30 00:00:00,2021-04-30 00:00:00,294801,2017-08-21 00:00:00,Recruiting
null,Phase 3 Clinical,C3,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,530,The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB,null,2018-08-20 12:00:00,2022-06-30 00:00:00,2022-06-30 00:00:00,228190,2016-04-30 00:00:00,Recruiting
null,Phase 1/Phase 2 Clinical,C12,ChAdOx1-85A,84564,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,72,EMaBS TB Vaccine Study,null,2021-03-22 12:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,354327,2018-12-01 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,moxifloxacin,12978,Bioequivalence,Mycobacterium tuberculosis infection,221,N,26,"Bioequivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions",2012-12-31 00:00:00,2014-06-03 00:00:00,null,2012-12-31 00:00:00,218651,2012-11-30 00:00:00,Completed
null,Phase Not Applicable,PNA,68Ga-tilmanocept,116061,Safety,Mycobacterium tuberculosis infection,221,N,null,A comparative study to evaluate the use of 68Ga-tilmanocept in patients with tuberculosis (TB),null,null,null,null,378644,null,Planned
null,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,750,Evaluating Newly Approved Drugs for Multidrug-resistant TB,null,2019-04-02 00:00:00,2021-04-30 00:00:00,2021-04-30 00:00:00,259506,2016-12-31 00:00:00,Recruiting
null,Phase 2/Phase 3 Clinical,C23,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,630,Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s),null,2019-05-23 12:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,244304,2017-01-31 00:00:00,Recruiting
null,Phase 2/Phase 3 Clinical,C23,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,238,Treatment Shortening of MDR-TB Using Existing and New Drugs,null,2018-05-22 12:00:00,2021-06-30 00:00:00,2021-06-30 00:00:00,247456,2016-01-31 00:00:00,Recruiting
null,Phase 1/Phase 2 Clinical,C12,MTBVAC,89744,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,120,MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa,null,2021-05-15 12:00:00,2021-03-15 00:00:00,2021-03-15 00:00:00,275657,2019-01-24 00:00:00,Recruiting
null,Phase 4 Clinical,C4,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 2 Clinical,C2,pravastatin,4155,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,40,Statin Adjunctive Therapy for TB,null,2021-12-04 12:00:00,2021-09-01 00:00:00,2021-09-01 00:00:00,331728,2019-08-15 00:00:00,Not yet recruiting
null,Phase 2b Clinical,C2B,pretomanid,13323,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,183,Assessing PA-824 for Tuberculosis,null,2017-08-18 12:00:00,2021-09-30 00:00:00,2021-09-30 00:00:00,213394,2015-04-29 00:00:00,Recruiting
null,Phase 1 Clinical,C1,GX-70,53019,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,Safety and Immunogenicity Study of GX-70 in TB Patient,2018-08-31 00:00:00,2020-07-20 12:00:00,null,2018-08-31 00:00:00,298965,2018-03-31 00:00:00,Terminated
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,60,Pharmacokinetic Study to Evaluate Anti-Mycobacterial Activity of TMC-207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB,null,2018-08-23 12:00:00,2025-07-13 00:00:00,2025-07-13 00:00:00,221523,2016-05-03 00:00:00,Recruiting
null,Phase 3 Clinical,C3,pretomanid,13323,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,284,Shortening Treatment by Advancing Novel Drugs,2018-05-31 00:00:00,2017-06-19 12:00:00,null,2018-05-31 00:00:00,221844,2015-02-28 00:00:00,Completed
null,Phase 2 Clinical,C2,everolimus,13340,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,200,TB Host Directed Therapy,null,2019-03-22 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,279898,2016-11-30 00:00:00,No longer recruiting
null,Phase 2/Phase 3 Clinical,C23,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,450,"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients",null,2020-11-18 12:00:00,2022-01-31 00:00:00,2022-01-31 00:00:00,319125,2018-07-30 00:00:00,Recruiting
null,Phase 4 Clinical,C4,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,3900,Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis,null,2018-12-21 12:00:00,2018-12-31 00:00:00,2018-12-31 00:00:00,271641,2016-08-31 00:00:00,Recruiting
null,Phase 1 Clinical,C1,faropenem,4492,"Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,36,Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers,2015-10-31 00:00:00,2017-01-28 00:00:00,null,2015-10-31 00:00:00,224811,2015-02-28 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,delamanid,16545,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,238,Treatment Shortening of MDR-TB Using Existing and New Drugs,null,2018-05-22 12:00:00,2021-06-30 00:00:00,2021-06-30 00:00:00,247456,2016-01-31 00:00:00,Recruiting
null,Phase 1 Clinical,C1,rifabutin,4229,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,15,Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects,2017-09-06 00:00:00,2019-08-12 12:00:00,null,2017-09-06 00:00:00,298711,2017-06-06 00:00:00,Completed
null,Phase 1 Clinical,C1,bedaquiline,51310,"Safety,Bioequivalence,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,24,TASK-002: Bioequivalence of Bedaquiline 400 mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions,2017-01-11 00:00:00,2019-03-02 12:00:00,null,2017-01-11 00:00:00,286376,2016-11-10 00:00:00,Completed
null,Phase 4 Clinical,C4,gatifloxacin,7017,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,140,"Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis",null,2012-03-22 12:00:00,2010-12-31 00:00:00,2010-12-31 00:00:00,328802,2009-12-01 00:00:00,No longer recruiting
null,Phase 2 Clinical,C2,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,220,Refining MDR-TB Treatment Regimens for Ultra Short Therapy,null,2021-08-20 12:00:00,2022-12-01 00:00:00,2022-12-01 00:00:00,372676,2019-05-01 00:00:00,Not yet recruiting
null,Phase 1/Phase 2 Clinical,C12,delamanid,16545,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,125,A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis,null,2021-02-13 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,353987,2018-10-25 00:00:00,Recruiting
null,Phase 2b Clinical,C2B,moxifloxacin,12978,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,75,PanACEA Sutezolid Dose-finding and Combination Evaluation,null,2021-12-20 12:00:00,2020-02-29 00:00:00,2020-02-29 00:00:00,381674,2019-08-31 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,180,"Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB",null,2020-02-20 12:00:00,2022-01-31 00:00:00,2022-01-31 00:00:00,293734,2017-10-31 00:00:00,Recruiting
null,Phase 1/Phase 2 Clinical,C12,moxifloxacin,12978,Efficacy,Mycobacterium tuberculosis infection,221,N,250,Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis,null,2021-07-31 00:00:00,null,null,374838,2019-05-01 00:00:00,Not yet recruiting
null,Phase 2 Clinical,C2,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,146,Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis,2008-09-01 00:00:00,2007-02-20 12:00:00,null,2008-09-01 00:00:00,8791,2004-10-31 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,pretomanid,13323,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,450,"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients",null,2020-11-18 12:00:00,2022-01-31 00:00:00,2022-01-31 00:00:00,319125,2018-07-30 00:00:00,Recruiting
null,Phase 2 Clinical,C2,"ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82091,Efficacy,Mycobacterium tuberculosis infection,221,N,474,Appropriate course of the treatment of tuberculous pleurisy,null,2017-09-20 12:00:00,null,null,309137,2015-06-01 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,AERAS-402,53975,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,24,"An open-label, phase I trial to evaluate the safety, tolerability and immunogenicity of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection",2007-05-11 00:00:00,2009-02-13 12:00:00,null,2007-05-11 00:00:00,8497,2006-10-25 00:00:00,Completed
null,Phase not specified,NS,ofloxacin,52139,Efficacy,Mycobacterium tuberculosis infection,221,N,217,"A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)",null,2007-03-17 12:00:00,2006-01-01 00:00:00,2006-01-01 00:00:00,152200,2004-11-25 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,rifapentine,15102,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,72,Tuberculosis Clinical Trials Consortium Study 35,null,2022-01-19 12:00:00,2022-02-28 00:00:00,2022-02-28 00:00:00,359122,2019-09-30 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,SSI H56-IC31,74849,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,39,Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic,null,2018-03-21 12:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,235355,2015-11-30 00:00:00,No longer recruiting
null,Phase 1 Clinical,C1,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,16,TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer,2009-05-31 00:00:00,2011-05-06 12:00:00,null,2009-05-31 00:00:00,42128,2009-02-28 00:00:00,Completed
null,Phase 3 Clinical,C3,delamanid,16545,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,5610,Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients,null,2021-09-22 12:00:00,2025-06-18 00:00:00,2025-06-18 00:00:00,344335,2019-06-03 00:00:00,Recruiting
null,Phase 3 Clinical,C3,rifapentine,15102,Efficacy,Mycobacterium tuberculosis infection,221,N,3000,Study for latent tuberculosis infection intervention among close contacts of pulmonary tuberculosis patients,null,2020-09-29 12:00:00,2022-12-31 00:00:00,2022-12-31 00:00:00,361821,2018-06-10 00:00:00,Recruiting
null,Phase 2b Clinical,C2B,delamanid,16545,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,75,PanACEA Sutezolid Dose-finding and Combination Evaluation,null,2021-12-20 12:00:00,2020-02-29 00:00:00,2020-02-29 00:00:00,381674,2019-08-31 00:00:00,Not yet recruiting
null,Phase 4 Clinical,C4,rifapentine,15102,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,38,The safety and efficacy of high dose rifapentine in treatment of tuberculosis,null,2021-04-22 12:00:00,2020-01-01 00:00:00,2020-01-01 00:00:00,359664,2019-01-01 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,H4:IC31,48499,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,70,"A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-negative, TB-negative, BCG-naive Adults",2013-11-30 00:00:00,2013-05-22 12:00:00,null,2013-11-30 00:00:00,227111,2011-01-31 00:00:00,Completed
null,Phase Not Applicable,PNA,OPC-167832,104447,Safety,Mycobacterium tuberculosis infection,221,Y,null,A multiple-ascending-dose and early-bactericidal-activity study to assess OPC-167832 in drug susceptible TB patients,null,2021-04-21 12:00:00,null,null,327016,2018-12-31 00:00:00,Planned
null,Phase 2 Clinical,C2,SSI H56-IC31,74849,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,A Phase II Study of H56:IC31 in Healthy Adolescents,null,2020-10-19 12:00:00,null,null,310653,2018-06-30 00:00:00,Terminated
null,Phase 1/Phase 2 Clinical,C12,OPC-167832,104447,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,125,A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis,null,2021-02-13 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,353987,2018-10-25 00:00:00,Recruiting
null,Phase 2 Clinical,C2,dolutegravir,59062,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,84,"Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis",null,2019-01-30 00:00:00,2021-01-15 00:00:00,2021-01-15 00:00:00,243619,2016-08-31 00:00:00,No longer recruiting
null,Phase 1 Clinical,C1,cabotegravir,69974,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,15,Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects,2017-09-06 00:00:00,2019-08-12 12:00:00,null,2017-09-06 00:00:00,298711,2017-06-06 00:00:00,Completed
null,Phase 4 Clinical,C4,emtricitabine,4728,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,200,RIFART,2011-04-19 00:00:00,2007-05-21 12:00:00,null,2011-04-19 00:00:00,131240,2005-03-15 00:00:00,Terminated
null,Phase 2 Clinical,C2,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,240,Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in HIV-positive Adults,2015-06-04 00:00:00,2013-05-08 12:00:00,null,2015-06-04 00:00:00,73200,2011-01-17 00:00:00,Completed
null,Phase 2 Clinical,C2,lopinavir + ritonavir,14681,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,47,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam,2012-09-30 00:00:00,2012-10-19 12:00:00,null,2012-09-30 00:00:00,11188,2010-06-30 00:00:00,Completed
null,Phase 4 Clinical,C4,"tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences",49219,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,780,Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis,2010-07-31 00:00:00,2008-11-05 12:00:00,null,2010-07-31 00:00:00,10681,2006-08-31 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,atorvastatin,2807,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial,null,2016-04-07 12:00:00,null,null,199754,2014-01-31 00:00:00,Terminated
null,Phase 4 Clinical,C4,nevirapine,3700,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,39,Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study),2017-07-31 00:00:00,2015-02-05 12:00:00,null,2017-07-31 00:00:00,89135,2012-11-30 00:00:00,Completed
null,Phase 1 Clinical,C1,bedaquiline,51310,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,32,Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects,2010-05-31 00:00:00,2012-06-30 00:00:00,null,2010-05-31 00:00:00,208141,2010-03-31 00:00:00,Completed
null,Phase 4 Clinical,C4,ritonavir,7310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,9,Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin,2018-12-31 00:00:00,2018-05-30 00:00:00,null,2018-12-31 00:00:00,93494,2016-02-29 00:00:00,Terminated
null,Phase 2 Clinical,C2,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,142,Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With Tuberculosis (TB) Disease,2014-04-10 00:00:00,2014-03-05 12:00:00,null,2014-04-10 00:00:00,80383,2011-11-14 00:00:00,Terminated
null,Phase 4 Clinical,C4,itraconazole,3411,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,60,A Comparative Study of Itraconazole in Various Doses Schedule in the Treatment of Pulmonary Aspergilloma in Treated  with the Patients of Pulmonary Tuberculosis,null,2014-11-20 12:00:00,null,null,131456,2012-07-31 00:00:00,Recruiting
null,Phase 1 Clinical,C1,MVA-85A,55317,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,20,"The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV",2010-07-31 00:00:00,2009-02-04 12:00:00,null,2010-07-31 00:00:00,10868,2006-11-30 00:00:00,Completed
null,Phase not specified,NS,rifapentine,15102,Efficacy,Mycobacterium tuberculosis infection,221,Y,722,"An open-label, active control trial of rifapentine to evaluate efficacy, in patients with pulmonary tuberculosis",null,2001-04-21 12:00:00,null,null,15328,1998-12-31 00:00:00,Status not specified
null,Phase 4 Clinical,C4,Fluzone,44409,Efficacy,Mycobacterium tuberculosis infection,221,N,301,Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults,2014-11-20 00:00:00,2016-06-05 12:00:00,null,2014-11-20 00:00:00,116439,2014-03-31 00:00:00,Completed
Asian Ancestry,Phase 2 Clinical,C2,lopinavir + ritonavir,14681,"Safety,Efficacy,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,35,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa,2010-10-31 00:00:00,2011-05-06 12:00:00,null,2010-10-31 00:00:00,11187,2009-02-28 00:00:00,Completed
Asian Ancestry,Phase not specified,NS,rifabutin,4229,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,39,"A self-controlled, single-center Taiwanese study to assess the efficacy and tolerability of rifabutin for re-treating chronic cases of multidrug-resistant pulmonary tuberculosis",null,1999-04-22 12:00:00,null,null,15897,1996-12-31 00:00:00,Status not specified
null,Phase 3 Clinical,C3,nevirapine,3700,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,135,Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB,2013-02-28 00:00:00,2009-09-04 12:00:00,null,2013-02-28 00:00:00,114300,2007-06-30 00:00:00,Completed
null,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,152,Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide,null,2016-08-19 12:00:00,2016-04-30 00:00:00,2016-04-30 00:00:00,183613,2014-04-30 00:00:00,Recruiting
null,Phase 2 Clinical,C2,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,20,Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals Candidate Tuberculosis (TB) Vaccine GSK-692342,2013-05-24 00:00:00,2014-12-11 12:00:00,null,2013-05-24 00:00:00,90314,2012-08-21 00:00:00,Completed
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,65,Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With,2011-08-31 00:00:00,2013-02-19 12:00:00,null,2011-08-31 00:00:00,71107,2010-10-31 00:00:00,Completed
null,Phase 1 Clinical,C1,bedaquiline,51310,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,28,"A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants",2010-03-31 00:00:00,2011-12-21 12:00:00,null,2010-03-31 00:00:00,59134,2009-08-31 00:00:00,Completed
Asian Ancestry,Phase not specified,NS,efavirenz,10172,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,400,Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China,null,2011-05-06 12:00:00,2013-06-30 00:00:00,2013-06-30 00:00:00,76946,2009-02-28 00:00:00,Recruiting
null,Phase 4 Clinical,C4,lopinavir + ritonavir,14681,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,39,Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study),2017-07-31 00:00:00,2015-02-05 12:00:00,null,2017-07-31 00:00:00,89135,2012-11-30 00:00:00,Completed
null,Phase 1 Clinical,C1,bedaquiline,51310,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,16,"A Study to Investigate Pharmacokinetics, Safety and Tolerability of TMC-207 in Patients With Moderately Impaired Hepatic Function",2011-01-31 00:00:00,2012-03-18 12:00:00,null,2011-01-31 00:00:00,61895,2010-01-31 00:00:00,Completed
null,Phase 3 Clinical,C3,stavudine,4481,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,540,Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis,2010-05-31 00:00:00,2008-04-07 12:00:00,null,2010-05-31 00:00:00,145651,2006-01-31 00:00:00,Completed
null,Phase 4 Clinical,C4,lopinavir + ritonavir,14681,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,200,RIFART,2011-04-19 00:00:00,2007-05-21 12:00:00,null,2011-04-19 00:00:00,131240,2005-03-15 00:00:00,Terminated
null,Phase not specified,NS,lopinavir + ritonavir,14681,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,90,"An Open-Label, Sequential Non-Randomized Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir Superboosted With Ritonavir (1 : 1 Ratio) in the Presence of Rifampicin or Lopinavir Boosted With Ritonavir (4 : 1 Ratio) in the Absence of Rifampicin in HIV and TB Co-Infected Children in South Africa",null,2015-03-23 12:00:00,2014-07-01 00:00:00,2014-07-01 00:00:00,142540,2012-12-01 00:00:00,Recruiting
null,Phase 3 Clinical,C3,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,200,Latency in Pulmonary Tuberculosis,null,2012-06-19 12:00:00,2015-02-28 00:00:00,2015-02-28 00:00:00,67984,2010-02-28 00:00:00,Recruiting
null,Phase 1b Clinical,C1B,"ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis",68617,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,66,"Phase I, ID93 + GLA-SE Vaccine Trial in BCG-vaccinated Healthy Adult Volunteers",2015-07-31 00:00:00,2016-01-20 12:00:00,null,2015-07-31 00:00:00,151743,2013-09-30 00:00:00,Completed
null,Phase not specified,NS,sutezolid,11088,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,59,"PK and Bactericidal Activity in Sputum and Blood of PNU-100480 (Sutezolid, U-480) and its Major Metabolite (PNU-101603, U-603) in Patients with Pulmonary TB",2012-09-12 00:00:00,null,null,2012-09-12 00:00:00,128346,null,Completed
null,Phase not specified,NS,lopinavir + ritonavir,14681,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,null,A Study to Evaluate Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected with HIV and TB,null,2014-06-12 00:00:00,2015-01-12 00:00:00,2015-01-12 00:00:00,147644,2012-01-12 00:00:00,Not yet recruiting
Asian Ancestry,Phase not specified,NS,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,16,"A hospital-based retrospective study to assess the clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China",null,null,null,null,234062,null,Status not specified
null,Phase 1 Clinical,C1,pretomanid,13323,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,74,Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers,2012-12-31 00:00:00,2015-01-20 12:00:00,null,2012-12-31 00:00:00,90512,2012-09-30 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,linezolid,11036,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,300,An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis,null,2018-02-19 12:00:00,2019-01-31 00:00:00,2019-01-31 00:00:00,230529,2015-10-31 00:00:00,Recruiting
null,Phase 1 Clinical,C1,rifabutin,4229,"Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,44,Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis,null,2002-05-02 12:00:00,null,null,10646,2000-02-25 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,rifabutin,4229,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,102,Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB,2004-11-30 00:00:00,2001-10-05 12:00:00,2002-11-30 00:00:00,2004-11-30 00:00:00,10652,1999-07-31 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,linezolid,11036,Safety,Mycobacterium tuberculosis infection,221,N,36,Pilot Study Examining the Safety and Tolerability of Low Dose Linezolid in the Treatment of Multi-Drug Resistant Tuberculosis,2010-09-01 00:00:00,2011-08-20 12:00:00,null,2010-09-01 00:00:00,11219,2009-04-30 00:00:00,Completed
null,Phase 4 Clinical,C4,nelfinavir,8255,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,20,Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB,2005-06-30 00:00:00,2002-05-06 12:00:00,2002-02-28 00:00:00,2005-06-30 00:00:00,10656,2000-02-29 00:00:00,Completed
null,Phase 1/Phase 2 Clinical,C12,ritonavir,7310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,20,The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin,2009-12-31 00:00:00,2009-03-07 12:00:00,2009-06-30 00:00:00,2009-12-31 00:00:00,10871,2006-12-31 00:00:00,Completed
null,Phase 4 Clinical,C4,nevirapine,3700,Pharmacokinetics,Mycobacterium tuberculosis infection,221,N,18,Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis,2010-12-31 00:00:00,2010-08-06 12:00:00,null,2010-12-31 00:00:00,11184,2008-05-31 00:00:00,Completed
null,Phase 2 Clinical,C2,moxifloxacin,12978,Efficacy,Mycobacterium tuberculosis infection,221,N,69,Essentiality of INH in TB Therapy,2016-02-10 00:00:00,2017-10-19 12:00:00,null,2016-02-10 00:00:00,87091,2015-06-30 00:00:00,Completed
null,Phase 3 Clinical,C3,nevirapine,3700,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,116,Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment,null,2008-11-28 00:00:00,2011-12-31 00:00:00,2011-12-31 00:00:00,10863,2006-06-30 00:00:00,Suspended
null,Phase 2/Phase 3 Clinical,C23,IMM-201,11115,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,null,A phase II/III study to evaluate the safety and efficacy of SRL-172 for the treatment of tuberculosis,null,2000-04-21 12:00:00,null,null,19996,1997-12-31 00:00:00,Suspended
null,Phase 2 Clinical,C2,pascolizumab,17132,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,32,Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis,null,2014-10-20 12:00:00,2017-07-31 00:00:00,2017-07-31 00:00:00,89066,2012-06-30 00:00:00,No longer recruiting
null,Phase 2 Clinical,C2,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,36,"An Open-Label Study to Evaluate the Effects on Mycobacterium Tuberculosis, Safety, Tolerability and Pharmacokinetics of Single Doses of R-207910, in Treatment Naive Patients With Mycobacterium Tuberculosis Infection",null,2007-02-07 12:00:00,null,null,129536,2004-10-18 00:00:00,Recruiting
null,Phase 1 Clinical,C1,bedaquiline,51310,"Safety,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,36,A Study to Assess the Relative Bioavailability of TMC-207 Following Single-dose Administrations of Two Pediatric Formulations in Healthy Adult Participants,2013-08-31 00:00:00,2015-08-20 12:00:00,null,2013-08-31 00:00:00,114087,2013-04-30 00:00:00,Completed
Asian Ancestry,Phase 2 Clinical,C2,rifabutin,4229,"Safety,Efficacy,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,35,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa,2010-10-31 00:00:00,2011-05-06 12:00:00,null,2010-10-31 00:00:00,11187,2009-02-28 00:00:00,Completed
null,Phase 2 Clinical,C2,lopinavir + ritonavir,14681,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,40,Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw,null,2017-09-04 12:00:00,2019-09-30 00:00:00,2019-09-30 00:00:00,226826,2015-06-30 00:00:00,Recruiting
null,Phase 2 Clinical,C2,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,121,Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis,null,2012-03-21 12:00:00,null,null,23035,2009-11-30 00:00:00,Terminated
null,Phase 1 Clinical,C1,TBA-354,71742,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,48,"A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TBA-354 in Healthy Adult Subjects",2015-06-30 00:00:00,2017-05-22 12:00:00,null,2015-06-30 00:00:00,215600,2015-01-31 00:00:00,Completed
null,Phase 1 Clinical,C1,AEC/BC02,81363,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,175,Clinical study of freeze - dried recombinant tuberculosis vaccine (AEC/BC02),null,null,null,null,291253,null,Not yet recruiting
null,Phase 1a Clinical,C1A,"small molecule therapeutic, Beijing Union Pharmaceutical Factory/Institute of Materia Medica",101474,"Safety,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,Y,58,The phase Ia clinical trial of pyrifazimine,null,2021-01-20 12:00:00,2019-12-31 00:00:00,2019-12-31 00:00:00,356451,2018-10-01 00:00:00,Not yet recruiting
null,Phase 2/Phase 3 Clinical,C23,rifapentine,15102,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,900,A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis,null,2020-07-10 12:00:00,2022-03-12 00:00:00,2022-03-12 00:00:00,333435,2018-03-21 00:00:00,Recruiting
null,Phase 2 Clinical,C2,cefadroxil,46931,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,45,Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers,null,2021-03-21 12:00:00,2019-05-30 00:00:00,2019-05-30 00:00:00,360329,2018-11-30 00:00:00,Not yet recruiting
Asian Ancestry,Phase 2 Clinical,C2,lamivudine,3474,"Safety,Efficacy,Bioavailability,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,35,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa,2010-10-31 00:00:00,2011-05-06 12:00:00,null,2010-10-31 00:00:00,11187,2009-02-28 00:00:00,Completed
null,Phase 2/Phase 3 Clinical,C23,moxifloxacin,12978,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,300,An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis,null,2018-02-19 12:00:00,2019-01-31 00:00:00,2019-01-31 00:00:00,230529,2015-10-31 00:00:00,Recruiting
null,Phase 1a Clinical,C1A,macozinone,90085,"Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,Y,32,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ-169 Formulation",2018-03-28 00:00:00,2020-03-26 12:00:00,null,2018-03-28 00:00:00,328144,2017-12-05 00:00:00,Completed
null,Phase not specified,NS,levofloxacin,3492,Efficacy,Mycobacterium tuberculosis infection,221,N,null,The research of new regimen for multidrug-resistant tuberculosis treatment,null,2011-01-21 12:00:00,2010-12-31 00:00:00,2010-12-31 00:00:00,244777,2008-10-01 00:00:00,No longer recruiting
null,Phase 2a Clinical,C2A,macozinone,90085,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,16,Phase IIa Study of PBTZ-169,2018-02-22 00:00:00,2019-04-07 12:00:00,null,2018-02-22 00:00:00,318771,2016-12-16 00:00:00,Terminated
null,Phase 1/Phase 2 Clinical,C12,levofloxacin,3492,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,120,Optimizing Treatment to Improve TBM Outcomes in Children,null,2019-05-11 00:00:00,2019-06-30 00:00:00,2019-06-30 00:00:00,278847,2017-02-22 00:00:00,Recruiting
null,Phase 3 Clinical,C3,delamanid,16545,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,A phase III study of delamanid in multidrug-resistant tuberculosis patients,null,null,null,null,323086,null,Status not specified
null,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,null,"Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin",null,2019-12-21 12:00:00,null,null,280651,2017-08-31 00:00:00,Terminated
null,Phase 2 Clinical,C2,meropenem,3616,"Safety,Efficacy,Pharmacokinetics,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,30,"Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis",2014-12-31 00:00:00,2017-01-19 12:00:00,null,2014-12-31 00:00:00,220739,2014-09-30 00:00:00,Completed
null,Phase 3 Clinical,C3,levofloxacin,3492,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,2006,"A randomized, controlled trial of 6 months of daily levofloxacin for the prevention of tuberculosis among household contacts of patients with multi-drug resistant tuberculosis",null,2018-07-04 12:00:00,null,null,269403,2016-03-14 00:00:00,Recruiting
null,Phase 4 Clinical,C4,rifabutin,4229,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,80,Research on New Regimens for Retreatment Pulmonary Tuberculosis,null,2015-10-20 12:00:00,2016-12-31 00:00:00,2016-12-31 00:00:00,220243,2013-06-30 00:00:00,Recruiting
null,Phase 1 Clinical,C1,pretomanid,13323,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,null,"A phase I trial to evaluate the safety, tolerability, pharmacokinetics of a single dose of PA-824",null,2007-10-04 12:00:00,null,null,9416,2005-06-14 00:00:00,Status not specified
null,Phase 2a Clinical,C2A,meropenem,3616,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,88,Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB,null,2019-12-13 12:00:00,2022-07-31 00:00:00,2022-07-31 00:00:00,300655,2017-08-23 00:00:00,Recruiting
null,Phase 2 Clinical,C2,rifabutin,4229,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,230,Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis,null,2020-08-28 12:00:00,2020-12-31 00:00:00,2020-12-31 00:00:00,334027,2018-04-15 00:00:00,Recruiting
null,Phase 4 Clinical,C4,rifabutin,4229,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 2a Clinical,C2A,telacebec,85970,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,Y,60,"A Phase II Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q-203)",null,2020-11-11 12:00:00,2020-01-31 00:00:00,2020-01-31 00:00:00,343604,2018-07-23 00:00:00,No longer recruiting
null,Phase 1 Clinical,C1,telacebec,85970,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,30,"A phase I, singlecenter, open-label, prospective clinical study to assess safety, tolerability and pharmacokinetics of ascending doses of Q-203 in single use in healthy subjects",2017-06-22 00:00:00,null,null,2017-06-22 00:00:00,371518,null,Completed
null,Phase 4 Clinical,C4,pretomanid,13323,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,448,The Individualized M(X) Drug-resistant TB Treatment Strategy Study,null,2019-08-20 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,307654,2017-06-14 00:00:00,Recruiting
null,Phase 2 Clinical,C2,rifapentine,15102,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,566,Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis,null,2021-03-22 12:00:00,2022-06-01 00:00:00,2022-06-01 00:00:00,375813,2018-12-01 00:00:00,Recruiting
null,Phase 1 Clinical,C1,BTZ-043,70901,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,30,A Single Ascending Dose Study Of BTZ-043,2019-03-05 00:00:00,2020-09-26 12:00:00,null,2019-03-05 00:00:00,346718,2018-06-07 00:00:00,Completed
null,Phase 1 Clinical,C1,AERAS-402,53975,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,30,"A double-blind, randomized, placebo-controlled, phase I study of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection",null,2009-08-30 22:47:27,null,null,8498,2007-05-11 10:47:27,Status not specified
null,Phase 2/Phase 3 Clinical,C23,bedaquiline,51310,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,900,A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis,null,2020-07-10 12:00:00,2022-03-12 00:00:00,2022-03-12 00:00:00,333435,2018-03-21 00:00:00,Recruiting
null,Phase 1 Clinical,C1,SSI H56-IC31,74849,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,22,A Phase I Study of Safety and Immunogenicity of AERAS-456 in HIV-Negative Adults Treated for Drug-susceptible Pulmonary TB,2016-10-24 00:00:00,2017-03-12 12:00:00,null,2016-10-24 00:00:00,223291,2014-11-21 00:00:00,Completed
null,Phase 1b Clinical,C1B,SSI H56-IC31,74849,"Safety,Efficacy,Pharmacodynamics",Mycobacterium tuberculosis infection,221,N,84,"Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents",2016-12-09 00:00:00,2017-09-19 12:00:00,null,2016-12-09 00:00:00,223463,2015-05-31 00:00:00,Completed
European Ancestry,Phase 1 Clinical,C1,RUTI,57308,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,24,Clinical Trial to Study Four Different Doses of the Vaccine RUTI in Healthy Volunteers,2008-06-01 00:00:00,2009-08-19 12:00:00,null,2008-06-01 00:00:00,8888,2007-04-30 00:00:00,Completed
null,Phase 1 Clinical,C1,"MTB72F vaccine (tuberculosis), GSK/ IAVI",9490,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,12,Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults,2004-12-01 00:00:00,2006-05-22 12:00:00,null,2004-12-01 00:00:00,23067,2004-01-31 00:00:00,Completed
Asian Ancestry,Phase 1 Clinical,C1,delpazolid,76307,"Safety,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,52,"Phase I study Evaluating the Safety, Tolerability and Pharmacokinetic Characteristics of RMX-2001",null,null,null,null,381962,null,Not yet recruiting
null,Phase 2/Phase 3 Clinical,C23,VPM-1002,55569,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,2000,Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence in India,null,2020-04-05 12:00:00,2019-11-20 00:00:00,2019-11-20 00:00:00,298671,2017-12-15 00:00:00,Recruiting
null,Phase 3 Clinical,C3,amoxicillin,44279,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,1875,Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis,null,2021-06-16 12:00:00,2020-06-30 00:00:00,2020-06-30 00:00:00,341686,2019-02-25 00:00:00,Recruiting
null,Phase 2 Clinical,C2,faropenem,4492,Efficacy,Mycobacterium tuberculosis infection,221,N,56,Synergistically acting Rifampicin and Faropenem in Tuberculosis,null,2021-09-19 12:00:00,null,null,377088,2019-05-31 00:00:00,Not yet recruiting
null,Phase 2/Phase 3 Clinical,C23,pretomanid,13323,Efficacy,Mycobacterium tuberculosis infection,221,N,54,Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial,null,2021-10-20 12:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,379769,2019-07-01 00:00:00,Not yet recruiting
null,Phase 3 Clinical,C3,bedaquiline,51310,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,500,The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB,null,2021-06-27 12:00:00,2021-12-31 00:00:00,2021-12-31 00:00:00,369109,2019-03-08 00:00:00,Recruiting
null,Phase 2 Clinical,C2,amoxicillin,44279,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,45,Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers,null,2021-03-21 12:00:00,2019-05-30 00:00:00,2019-05-30 00:00:00,360329,2018-11-30 00:00:00,Not yet recruiting
null,Phase 1 Clinical,C1,IMX-461,66409,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,Y,30,Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults,2014-12-31 00:00:00,2015-11-20 12:00:00,null,2014-12-31 00:00:00,142322,2013-07-31 00:00:00,Completed
null,Phase 4 Clinical,C4,etanercept,4567,"Safety,Efficacy",Mycobacterium tuberculosis infection,221,N,174,Risk of Tuberculosis and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh,null,2020-03-10 00:00:00,2019-12-31 00:00:00,2019-12-31 00:00:00,337163,2018-01-16 00:00:00,Recruiting
Asian Ancestry,Phase 2 Clinical,C2,dolutegravir,59062,"Safety,Efficacy,Pharmacokinetics",Mycobacterium tuberculosis infection,221,N,200,"Efficacy, Safety and Pharmacokinetics of DTG With RIF",null,2021-07-30 00:00:00,2021-03-31 00:00:00,2021-03-31 00:00:00,359086,2019-03-01 00:00:00,Not yet recruiting